This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Corvol, P. Articles by Jeunemaitre, X. Search for Related Content PubMed PubMed Citation Articles by Corvol, P. Articles by Jeunemaitre, X.

Molecular Genetics of Human Hypertension: Role of Angiotensinogen¹

INSERM U36, Collège de France, 75005 Paris, France

	Abstract

Top Abstract I. Introduction II. Structure of the... III. Characteristics of AGT IV. Tissue and Cellular... V. Regulation VI. Molecular Genetics of... VII. Molecular Genetics of... VIII. Effects of AGT... IX. Conclusions and Perspectives References

 

I. Introduction

II. Structure of the AGT Gene

III. Characteristics of AGT

A. AGT as the substrate for renin

B. AGT as a member of the serpin superfamily: other roles for AGT?

IV. Tissue and Cellular Distribution

V. Regulation

A. Hormonal regulation of AGT

B. Regulation of AGT in disease

C. Regulation of AGT gene transcription

VI. Molecular Genetics of AGT in Human Essential Hypertension

A. Strategies

B. Linkage studies

C. Association studies of AGT polymorphism and high blood pressure

D. Pregnancy-induced hypertension

E. M235T variants, plasma AGT concentration, and blood pressure

F. Association of AGT variants with the renal blood flow response to Ang II infusion

VII. Molecular Genetics of AGT and Other Diseases

A. AGT variants and coronary heart disease

B. AGT variants and complications of diabetes

C. AGT, obesity, and blood pressure

VIII. Effects of AGT Gene Variants and Gene Targeting on Ang I Production and Blood Pressure

A. Human studies

B. Genetic studies in rats and mice

C. Genetic hypertension in rats

D. Antisense AGT oligodeoxynucleotides

E. Transgenic animals

F. AGT gene duplication

IX. Conclusions and Perspectives

	I. Introduction

Top Abstract I. Introduction II. Structure of the... III. Characteristics of AGT IV. Tissue and Cellular... V. Regulation VI. Molecular Genetics of... VII. Molecular Genetics of... VIII. Effects of AGT... IX. Conclusions and Perspectives References

 
BLOOD pressure is regulated by a variety of mechanisms that involve the products of several genetic loci and a number of environmental factors. The heritable component of blood pressure has been documented in several studies of families and twins, and it is generally accepted that approximately 30% of the changes in blood pressure are attributable to genetic heritability and approximately 50% to environmental influences (1). Except for rare monogenic forms of hypertension such as glucocorticoid-suppressible hyperaldosteronism (2), Liddle’s syndrome (3), and apparent mineralocorticoid excess (4), little is known about the number of genes actually involved in human essential hypertension, their quantitative effect on blood pressure, their mode of transmission, or their interaction with other genes and environmental components.

Research on the molecular genetics of human hypertension developed less than 10 yr ago. Its goal was to identify the loci involved, to detect gene variants at the loci identified, to associate them with intermediate phenotypes, and ultimately to estimate their quantitative effects on blood pressure and their interaction with the principal environmental factors. The approach taken by several groups was to study candidate genes that may contribute to abnormal blood pressure because of their known effect on the cardiovascular system. The genes of the renin-angiotensin system have been most extensively studied because of the well documented role of this system in the control of blood pressure and in the pathogenesis of several forms of hypertension.

Renin acts on a single substrate, angiotensinogen (AGT), which is synthesized mainly by the liver and released into the circulation. In association with the Utah group, we first identified the role of AGT gene polymorphism in human essential hypertension (5). Several AGT gene variants were discovered, and one of them was found to be associated with an increase in plasma AGT and hypertension. A number of linkage and association studies have since examined several clinical situations and various populations. This review will discuss briefly the structure of the AGT gene, the principal characteristics of the protein, and its tissue distribution and regulation and will analyze the findings of genetic studies that support the role of AGT in human hypertension and certain other cardiovascular diseases.

	II. Structure of the AGT Gene

Top Abstract I. Introduction II. Structure of the... III. Characteristics of AGT IV. Tissue and Cellular... V. Regulation VI. Molecular Genetics of... VII. Molecular Genetics of... VIII. Effects of AGT... IX. Conclusions and Perspectives References

 
The human AGT cDNA is 1,455 nucleotides long and codes for a 485-amino acid protein (6). The AGT gene contains five exons and four introns, which span 13 kb (Fig. 1). The first exon (37 bp) codes for the 5'-untranslated region of the mRNA. There are two potential ATG sites, and the second exon codes for a signal peptide of 24 or 33 residues and the first 252 amino acids (59%) of the mature protein. Mature AGT contains 452 amino acid residues; the first ten amino acids correspond to angiotensin I (Ang I), and the other larger portion corresponds to des(Ang I)AGT. Exon 3 codes for 90 amino acids and exon 4 codes for 48 residues. Exon 5 contains a short coding sequence (62 amino acids), followed by a long 3'-untranslated sequence with two polyadenylation signals, accounting for the existence of two mRNA species differing in length by 200 nucleotides (7).

View larger version (16K): [in this window] [in a new window]   Figure 1. Schematic structure of the AGT gene, mRNAs, and proteins [Derived from Ref. 6.]

	III. Characteristics of AGT

Top Abstract I. Introduction II. Structure of the... III. Characteristics of AGT IV. Tissue and Cellular... V. Regulation VI. Molecular Genetics of... VII. Molecular Genetics of... VIII. Effects of AGT... IX. Conclusions and Perspectives References

 
Human AGT is a globular glycoprotein with a molecular mass between 55 and 65 kDa, depending on its state of glycosylation. It contains four putative N-linked glycosylation sites (Asn-X-Ser/Thr) that can be the origins of complex glycosylation chains. Although the role of this glycosylation process is not known in humans, the glycosylation status alters the AGT clearance rate in rats. The in vivo half-lives of two differently glycosylated forms of rat AGT are compatible with a two-compartment model and suggest that the more highly glycosylated form is secreted faster by the liver and eliminated more rapidly by the kidney than is the less glycosylated form (17). There are four cysteine residues in the human mature protein, three of which are also present in rat and mice AGT, but there are only two in sheep AGT. The arrangement of their disulfide bridges is not known.

A high molecular mass form of AGT is present in human plasma, especially in pregnant women, where it accounts for about 15% of the total AGT. High molecular mass AGT is the predominant form of the protein in amniotic fluid (18). It has been shown recently to be a covalent complex between AGT and two other proteins (19). A major part is formed by a 2:2 complex of AGT and the proform of a placental protein, the eosinophil major basic protein (proMBP); the proteins probably interact through disulfide bonds. A fraction of this complex seems to bind two molecules of complement C3dg in a 2:2:2 pattern to give a 300-kDa complex. The function of high molecular mass AGT is not known.

AGT is usually measured by an enzymatic assay for Ang I after its complete hydrolysis by excess renin. Direct immunoassays, using polyclonal and monoclonal antibodies against AGT, that measure both intact AGT and its inactive C-terminal part, des(Ang I)AGT, have also been developed (20). This technique accurately quantifies AGT in tissues such as the liver, which contains mainly enzymes capable of metabolizing Ang I, making the interpretation of the enzymatic assay difficult (21).

A. AGT as the substrate for renin
The rate-limiting step in the cascade of enzymatic events that make up the circulating renin-angiotensin system is the first step, the cleavage of AGT by renin. The plasma AGT concentration is in the micromolar range, whereas the plasma renin concentration is 1000 times lower. AGT is present in both the plasma and extracellular fluids and can be considered to be a "reservoir" for the action of renin. Another reservoir of AGT is the cerebrospinal fluid, which has the highest proportion of AGT (per mg of total protein) of all biological fluids (20, 22). Short-term regulation of the renin-angiotensin system does not seem to depend on changes in the plasma AGT concentration. For example, the rapid adaptation to changes in sodium intake is mediated by an abrupt change in the amount of renin released (which can vary more than 10-fold) by the renal juxtaglomerular (JG) cells (occurring within seconds or minutes), but changes in plasma AGT concentration are rather slow (occurring over hours or days).

The limiting role of AGT in the generation of plasma Ang I and therefore of plasma angiotensin II (Ang II), since angiotensin converting enzyme (ACE) is not rate limiting, is of great importance for evaluating its exact role in blood pressure regulation and hypertension. The affinity of renin for its substrate, its Michaelis-Menton constant (K_m), is about 1.25 ± 0.1 µmol/liter, more than 10-fold lower than the K_m for the homologous synthetic tetradecapeptide renin substrate (20.7 ± 7 µmol/liter) (23, 24). As the plasma AGT concentrations in rats and humans are about 1 µmol/liter, the plasma AGT would have to be 10-times greater for its hydrolysis to be a zero-order reaction. Hence the large amount of AGT in the plasma probably does not provide an excess of substrate for renin. Before genetic studies were undertaken, there was direct in vivo evidence for the limiting role of plasma AGT in Ang I generation from several independent sources. One was the decrease in blood pressure and PRA that occurs in rats after the injection of anti-AGT antibodies. The drop in blood pressure is dependent on the sodium balance and does not occur in bilaterally nephrectomized animals (25). The second was the increase in blood pressure that occurs after infusion of pure AGT into salt-depleted rats (26). These results suggest that the in vivo AGT concentration is most important for the activation of the renin system.

B. AGT as a member of the serpin superfamily: other roles for AGT?
The AGT gene belongs to the serpin (serine protease inhibitor) superfamily, which includes 1-antitrypsin, 1-antichymotrypsin, and antithrombin III. The structure of the AGT gene is similar to those of the other genes in terms of exon number, size, and splicing sites (27, 28). The structural similarity between AGT and these proteins (20% amino acid sequence identity) suggests that the genes of the serpin superfamily evolved from a primitive common ancestor some 500 million yr ago through a series of gene duplications, insertions, and deletions (28). AGT is probably one of the more distant members of the serpin superfamily and has probably lost its serine protease-inhibitory activity. Experiments conducted in this laboratory failed to show that AGT had any antiesterase activity when tested against various serine esterases (L. Wei, E. Clauser, and P. Corvol, unpublished observations).

AGT is an acute phase protein in the rat: its concentration increases markedly in response to inflammatory agents and tissue injury, but its function in these conditions is unknown (29, 30, 31). Its acute-phase response appears to be less marked in humans (32). Finally, the part of AGT remaining after renin cleavage, des(Ang I)AGT, has no known functions. Perhaps AGT [or des(Ang I)AGT] inhibits an unidentified proteolytic enzyme in these inflammatory states. AGT may stimulate the renin-angiotensin system locally in fever-induced vasodilatation, counteracting vasodilation and so helping to maintain blood pressure.

	IV. Tissue and Cellular Distribution

Top Abstract I. Introduction II. Structure of the... III. Characteristics of AGT IV. Tissue and Cellular... V. Regulation VI. Molecular Genetics of... VII. Molecular Genetics of... VIII. Effects of AGT... IX. Conclusions and Perspectives References

 
AGT is synthesized in the liver, and the plasma AGT concentration reflects mainly this synthesis. AGT is not stored in hepatocytes, but is constitutively secreted. Like other components of the renin-angiotensin system that are present in tissues involved in cardiovascular functions (33), AGT is synthesized in many tissues other than the liver. Even though these tissues produce less than in the liver, AGT appears to be an important component of the extravascular local renin-angiotensin system. Since the K_m of renin for AGT is relatively high, the rate of Ang I production by these systems is probably controlled by the local AGT concentration, rather than by the extravascular renin concentration. Other proteases in tissues may also hydrolyze AGT to Ang I (or even directly to Ang II) (34). The Ang II produced locally by these systems may have paracrine or autocrine effects. These tissue systems may well be regulated locally, independently of the circulating system.

The brain, large arteries, kidney, and adipose tissues are all established sites of AGT synthesis (35, 36, 37). In situ hybridization and immunohistochemistry studies have shown that glial cells are the most important source of AGT in the brain (38, 39, 40). Cultures of astrocytes from human brain tissue also produce AGT (41). It has been suggested that the AGT synthesized by glial cells is secreted and then taken up by neurons, thus forming a paracrine renin-angiotensin system (42). AGT is also present in the vascular walls, in the adventitia, and in the medial smooth muscle cell layer (43, 44, 45, 46). The principal AGT mRNA in the rat aorta seems to be in the brown adipose tissue (43). Thus the presence of highly vascularized adipose tissue around these vessels raises the possibility of a local angiotensin-generating system in which the adipose cells synthesize AGT. Ang II could then be generated by the actions of circulating renin and adventitial and/or endothelial ACE. There is, indeed, evidence for the local generation of angiotensin from AGT in isolated perfused rat blood vessels (47).

Most of the AGT mRNA in the heart is in the atria, and it is less abundant in the ventricles (35, 48). The presence of mRNA for the various components of the renin-angiotensin system, including Ang II receptors, in the heart is good evidence that the renin-angiotensin system has a physiological role in cardiac function. The amount of cardiac AGT appears to be hormonally regulated (35). Cardiac AGT mRNA is also increased in animals placed on a low-salt diet (49) and decreased in animals treated with ACE inhibitors (48).

AGT mRNA has been detected in the kidney (35, 50), mostly in proximal tubule cells (51). Changes in dietary sodium modulate the amount of AGT in the kidney: a low-salt diet increases the AGT mRNA in the proximal tubule cells (52), whereas the amount of AGT mRNA in the periaortic fat and liver remain unchanged. The renal AGT concentration, which also depends on circulating AGT (53), could be an important rate-limiting factor for the local generation of Ang I, at least during converting enzyme inhibition, and therefore a determining factor in the generation of renal angiotensin peptides and in the fine tuning of renal vascular resistance.

White adipose tissue, a rich source of AGT, is produced during the differentiation of preadipocytes to adipocytes (54). The recruitment of new fat cells could be enhanced by Ang II, via the release of prostaglandins that are adipogenic (55). The amount of AGT in white adipocytes in rats is influenced by their nutrition; it is reduced during fasting and increased with refeeding (56). The amounts of AGT protein and mRNA in retroperitoneal depots decline with age (57), suggesting that AGT is important for the growth of adipose tissue.

Finally, AGT mRNA has been detected in several other human tissues, such as the adrenal gland, where it is present in both the cortex and medulla (58). It could contribute, together with locally produced renin (59), to the paracrine generation of Ang II and the regulation of aldosterone secretion.

	V. Regulation

Top Abstract I. Introduction II. Structure of the... III. Characteristics of AGT IV. Tissue and Cellular... V. Regulation VI. Molecular Genetics of... VII. Molecular Genetics of... VIII. Effects of AGT... IX. Conclusions and Perspectives References

 
The plasma and tissue AGT concentrations both contribute directly to the circulating amounts of Ang I and Ang II. Thus, changes in these concentrations are important, as they can influence the degree of activation of the renin-angiotensin system. AGT is regulated by several hormonal factors, and some of the cis- and trans-regulatory elements involved in the regulation of its transcription have been identified.

A. Hormonal regulation of AGT
A wide variety of in vivo and in vitro models have been used by investigators to demonstrate that glucocorticoids (especially dexamethasone), estrogens, Ang II, and thyroid hormones all stimulate the synthesis and release of AGT (see reviews in Ref. 23 and in Refs. 60–62). These hormones increase the amount of AGT mRNA in the rat liver (35, 44, 63, 64). The hormonal regulation of AGT mRNA has also been studied in both hepatic (65) and nonhepatic cell lines, such as pancreatic cells (66) and adipocytes (56). The effects of steroids are neutralized by antiglucocorticoids and antiestrogens; thyroidectomy decreases the plasma AGT concentration, and T₃ restores it. Nevertheless, the stimulation of AGT synthesis by Ang II is still a matter of debate. While Ang II has been consistently found to stimulate the synthesis of AGT by cells in culture, a study in rats casts considerable doubt on its tonic influence on AGT production in vivo (67). The fall in plasma AGT that occurs during chronic ACE inhibition is probably due to an increase in its consumption due to the rise in plasma renin and to a decrease in its synthesis (68), although other mechanisms are possible since ACE inhibition does not block only the renin-angiotensin system.

The plasma concentrations of AGT and estrogens increase in parallel during pregnancy (69). Oral contraceptive pills containing synthetic estrogens also cause a dose-dependent increase in plasma AGT (70), but there seems to be no direct relationship between the increase in plasma AGT and blood pressure. However, there were subtle changes in renal blood flow in women whose circulating AGT concentrations were increased by ingestion of oral synthetic estrogens (71). This stimulatory effect is not observed when the estrogen is given percutaneously (72), perhaps because estradiol does not accumulate in hepatic cells.

Assuming that the rate of Ang I formation at the usual plasma AGT concentration is one-half maximal, it appears logical to suspect that the increase in AGT produced by synthetic estrogen or glucocorticoid treatment plays a role in the pathophysiology of some secondary forms of hypertension, such as oral contraceptive-induced hypertension (73), or Cushing’s syndrome (74). Similarly, the 3–5 mm Hg increase in systolic blood pressure that occurred in women taking high doses of synthetic estrogens as contraceptives might have been due to activation of the renin system through an increase in plasma AGT (75).

The estrogen-induced increase in AGT is tissue-dependent. The effect of estrogen on the liver is important, but it does not stimulate AGT production in adipose tissue, and contradictory results have been reported in brain (40). Campbell et al. (76) showed that the estrogen-induced increases in plasma AGT are associated with increases in renal angiotensin peptides, despite reduced plasma renin and angiotensin peptide concentrations. Bilateral nephrectomy also leads to an increase in the hepatic synthesis and plasma concentration of AGT (77), but the manner in which it does so is thus far unknown (23, 78, 79). The additive effects of these various stimuli suggest that they trigger AGT synthesis through different transcriptional pathways.

The observations described above suggest that a chronic increase in plasma AGT might facilitate hypertension in predisposed individuals, who may also have an abnormally short feedback loop between Ang II and renin release. The increase in plasma Ang II after an increase in plasma AGT exerts a short negative feedback loop on renin release in the normal physiological state, and this limits the direct effect of changes in plasma AGT on blood pressure.

B. Regulation of AGT in disease
Several pathological conditions lead to increased AGT production, which contributes to the local generation of Ang II. The medial layer of an injured aorta contains increased amounts of AGT mRNA, as might be expected for a member of the serpin family, which suggests that AGT is involved in myointimal proliferation in response to vascular injury (80). Increased ACE activity and AGT synthesis also occur after experimental left ventricular hypertrophy (81), suggesting, along with other studies, that the cardiac renin system may help modulate the growth and hypertrophy of the heart. The change in renal hemodynamics caused by experimental heart failure leads to a specific increase in renal AGT mRNA, suggesting that it contributes to the activation of the intrarenal renin system (82).

C. Regulation of AGT gene transcription
AGT production is probably regulated mainly by controlling gene transcription, although there is evidence for posttranscriptional regulation, as when Ang II increases the stability of AGT mRNA (83). The cis- and trans elements that regulate the AGT gene have been recently reviewed by Brasier and Li (84), and only those most relevant to AGT genetics will be summarized here. Recent studies in mice indicate that the proximal promoter region of the mouse AGT gene (-96 to +22) is sufficient for expression of the AGT gene in mouse fibroblast cells during their differentiation into adipocytes (85). A liver-specific (AGF2) factor binds to the proximal promoter element (-96 to +52), and an ubiquitous nuclear factor (AGF3) binds to the core promoter element (-6 to +22). These two factors seem to act synergistically (85). The core promoter region of the human AGT gene in HepG2 cells has been analyzed by the same group (86). Electrophoretic mobility shift assays demonstrated that an ubiquitously expressed nuclear factor (AGT core promoter binding factor 1, AGCF1) bound to a region between positions -25 to -1, denoted AGCE1 (AGT core promoter element 1) (see Fig. 2), located between the TATA box and the transcription initiation site. AGCE1 appears to play a major role in activating AGT transcription, in particular by the downstream core elements. This region is probably more complex with several nuclear factors binding to its 5'- or 3'-side (87), which may be important for the general rate of transcription initiation and also for determining the pattern of AGT gene expression. These studies point to the importance of these regulatory regions where several natural variants of the AGT gene have been detected.

View larger version (9K): [in this window] [in a new window]   Figure 2. Localization of the missense mutations observed at the AGT gene. 1 = L10F; 2 = T104M; 3 =174M; 4 = L209I; 5 = L211R; 6 = M235T; 7 = Y248C; 8 = L359M; 9 = V388M; (GT)n microsatellite marker is located at approximately 5 kb downstream the 3'-end of the AGT gene.

	VI. Molecular Genetics of AGT in Human Essential Hypertension

Top Abstract I. Introduction II. Structure of the... III. Characteristics of AGT IV. Tissue and Cellular... V. Regulation VI. Molecular Genetics of... VII. Molecular Genetics of... VIII. Effects of AGT... IX. Conclusions and Perspectives References

A. Strategies
A number of strategies can be used for genetic analysis of complex diseases, such as hypertension, in which several genes and environmental factors act in concert to determine the phenotype (88). In addition to developing genetic models of high blood pressure, three categories of statistical analysis can be used in humans. One is linkage analysis, in which sibling pairs are analyzed, the second is association studies, in which large numbers of cases and controls are analyzed, and the third is linkage-association studies, in which the association between a genetic marker and the disease within families is examined. Each method has its advantages and disadvantages. Most of them have been used to establish the relationships between hypertension and the AGT gene. The following brief discussion will give the reader a clearer understanding of the studies performed thus far.

Classic linkage studies, which test the cosegregation of a genetic marker and a trait, have been extremely useful for determining the genes involved in Mendelian traits. However, they require a specific genetic model, although some adjustments can be made. Use of the wrong model can lead to false positive or negative results, which makes the use of lod score analysis difficult in complex diseases that result from the interactions between several frequent susceptibility genes and the environment. Thus, allele-sharing methods, involving mainly sibling pairs, appear to be the best approach to testing the linkage between hypertension (taken here as qualitative trait) and genetic markers of a candidate gene (such as those of the renin-angiotensin system, and in this case AGT). This nonparametric approach does not require any a priori specification of the model for the inheritance of the trait and can be used on a single generation, thus avoiding some ambiguity about the age-related influence on blood pressure. The statistics are based on the number of alleles shared by the affected siblings compared with the random Mendelian distribution. While this is a robust method, it has relatively low statistical power and requires highly polymorphic markers and a large collection of well characterized sibling pairs. Such family collections have been identified so far in a few hypertension clinics. Another approach is to select sibling pairs contrasted for the trait (89). Although this strategy might appear more powerful, it is somewhat difficult to select individuals with low blood pressure values within a family in which hypertension is frequent.

The linkage analysis must be interpreted with caution regardless of which method is used. Samples that are too small, frequent disease-related alleles, and genetic heterogeneity are some of the reasons that might lead to false negative results. Conversely, a false estimation of the allele frequencies of a polymorphic marker, a low threshold of statistical significance, and a strategy of multiple testing of genes involved in the same hypertensive families can all lead to false positive results. These possibilities emphasize the need for using several approaches before declaring a locus to be the cause of a complex disease such as essential hypertension.

Association studies compare the frequencies of a marker (e.g., AGT gene polymorphism) in an affected population and in a control group (case-control study). Since it does not postulate any genetic model, this methodology is well suited to the detection of modest genetic effects within a complex and heterogeneous disease, such as high blood pressure (90). The statistical analysis is simple, based on a contingency table comparing the allele or the genotype frequencies. The probability of detecting an association between a candidate gene and the disease will depend on the allele frequency, the strength of its relationship with the disease, and the homogeneity of the population studied. A positive result may indicate a causal allele or an allele in linkage disequilibrium with the causal mutation. A negative result has almost no power, since it may be argued that other polymorphisms at the gene locus remain to be discovered. The main pitfall of this method is the possibility of false-positive results, mainly due to a population admixture and the failure to carefully select many well characterized cases and controls. As will be shown below, this problem is crucial for the M235T polymorphism of the AGT gene, whose allele frequency varies widely according to the subject’s ethnic origin. The use of an internal control within the family can provide a perfect match for ethnic ancestry. The haplotype relative risk method is based on a comparison of the genotype of the proband and the uninherited genotype (91). The transmission disequilibrium test is based on the frequency with which the associated allele transmitted from heterozygous parent to the affected proband (92).

Both linkage and association studies have been used to analyze the role of the AGT gene in essential hypertension and thus will be discussed separately.

B. Linkage studies
An extensive study of the potential role of the AGT gene in human essential hypertension was performed on two large series of hypertensive sibships yielding a total of 379 sibling pairs (Salt Lake City, UT, and Paris, France) (5). The highly polymorphic GT microsatellite located in the 3'-region of the AGT gene (11) and the powerful affected sibling pair methodology were used to obtain evidence of a genetic linkage between the AGT gene and hypertension in the whole set of families (5). A 17% excess of AGT allele sharing was found in severely hypertensive sibling pairs (subjects with a diastolic blood pressure above 100 mm Hg or being treated with two or more antihypertensive medications). While significant linkage was obtained in male pairs in both the Utah and Paris groups, no excess of shared AGT alleles was observed in female comparisons, suggesting the influence of an epistatic hormonal phenomenon. From these studies, it was estimated that mutations at the AGT locus might be a predisposing factor in at least 3–6% of hypertensive individuals younger than 60 yr of age. When the same methodology was used to analyze the same hypertensive sibling pairs from Utah or Paris, it showed no linkage with other genes of the renin system: renin (93), ACE (94), or Ang II type I receptor (95).

Two other linkage studies also indicate a relationship between the AGT locus and hypertension. Caulfield et al. (96) showed a strong linkage (25% excess of concordance) between the AGT gene locus and essential hypertension in a set of 63 British families. This linkage was also observed in the subgroup of patients with diastolic pressure above 100 mm Hg, but there was no difference among female-female pairs. However, there was no association between hypertension and the 174M or the 235T AGT variant in this population. The same group also found linkage and association of the AGT locus with high blood pressure in 63 affected sibling pairs of Africo-Caribbean origin (97), suggesting some similarity in the genetic basis of essential hypertension in populations of different ethnicity. The corroboration of these linkage studies, shown in Table 1, indicate that molecular variants of the AGT gene, such as M235T or those in linkage disequilibrium with this variant, are inherited predispositions to essential hypertension in humans.

The results of these studies must be interpreted with caution for several reasons. First, the frequency of the 235T (or 174 M) AGT allele varies from an ethnic group to another. The 235T allele is more frequent in the Asian (0.75) than in the Caucasian population (0.35) and is by far the predominant allele in the African population (up to 0.93 in Nigerians) (98, 99). As a consequence, positive results may arise from population admixture, and negative results in populations in which this allele is predominant may be due to the constraint of limited statistical power. Second, differences in the design of each study (especially interacting factors such as sex, age, body mass index) and the choice of the control group (which is critical in a case-control study) make any overall comparison difficult. For example, the negative study reported by Bennett et al. (100) deals with hypertensive subjects, both parents of which had histories of high blood pressure, which may lead to an aggregation of genes (100). Finally, most of the results reported to date have been obtained with relatively small numbers of patients, which can also generate false-negative or false-positive results. Because most studies linking AGT polymorphism and high blood pressure have clearly indicated the ethnicity of the populations, the results will be discussed accordingly.

1. Caucasians.
There are divergent results on the association between variants in AGT at position 235 (235T) or 174 (174M) and hypertension in Caucasians. Our original study (5) found that the M235T variant (Met Thr in amino acid position 235) was more frequent in hypertensive probands from Utah and Paris, especially in the more severe index cases (allele frequency: 0.50), than in controls (0.38). A subsequent study on 136 mild-to-moderate hypertensive subjects (101) also found that the frequency of the 235T allele was increased, although the increase was significant only for patients with a family history of hypertension. Schmidt et al. (102) also found a higher frequency of the 235T allele in subjects with hypertension, a family history of the disease, and early onset of hypertension. The effect of AGT gene polymorphism on blood pressure was studied in a genetic isolate, the Hutterite Brethren, in North America. Seven hundred forty one Hutterites were tested for an association between the systolic and diastolic blood pressure, and the M235T and T174M genotypes. There was a significant association between the resting systolic blood pressure and the 174M allele only in men (103): the AGT 174M allele accounted for 3% of the total variance in systolic blood pressure. A subsequent study showed an autosomal codominant effect of the AGT 174T allele on systolic blood pressure (104).

Other studies have not found any association between the 235T variant and hypertension. Caulfield et al. (96) found no association between hypertension and the 235T AGT variant in their study of 63 British families. Similar results were obtained by Barley (105) for 64 cases and 74 controls. These two studies on UK individuals showed similar frequencies in hypertensives (0.50), but quite different frequencies in normotensives (0.40). Bennett et al. (100) found no association in 92 individuals, who were offspring of two hypertensive parents and who were ascertained through self-referral. Fornage et al. (106) found no association in a population-based selection of 104 hypertensives with mild hypertension and 195 matched normotensives, but there was a surprising difference in the frequency of the T235 allele in normotensive men (0.47) and women (0.36). More recently, Hingorami et al. (107) found no difference in the frequency of M235T in 223 hypertensive subjects and 187 normotensive individuals in East Anglia in the United Kingdom. A more powerful study performed in Finland by Kiema et al. (108) gave negative results with 508 mild hypertensives and 523 population-based controls.

In any case, four large studies recently showed a positive association between the M235T allele and essential hypertension. An association with severe hypertension, with a stronger relationship for men than for women, was found in a sample from the Framingham Heart Study and from the Atherosclerosis Risk in Community study (ARIC), when the effects of body mass index and triglycerides were taken into account. The proportions of cases attributable to the 235T allele were 8% in the ARIC population and 20% in the Framingham population (109). In a study testing a large number of AGT alleles, the frequency of the 235T allele was 0.47 in the 477 probands of hypertensive families and 0.38 (P = 0.004) in the 364 Caucasian controls (110). In a cross-sectional sample of 634 middle-aged subjects from the MONICA Augsburg cohort, Schunkert et al. (111) found that individuals carrying at least one copy of the T235 allele had higher systolic and diastolic blood pressures and were more likely to use antihypertensive drugs. Finally, another case-control study involving 802 hypertensive subjects and 658 Caucasian controls has shown a significant increase in the frequency of the T235 allele in men (0.46 vs. 0.40, P = 0.003) and in women whose hypertension was diagnosed before they were 45 yr of age (L. Tiret, H. Blanc, J. B. Ruivadets, D. Arveiler, G. Luc, X. Jeunemaitre, J. Tichet, C. Mallet, O. Poirier, P. F. Plovin, and F. Cambien, submitted). These studies emphasize the importance of sample size testing for susceptibility locus in a complex disease such as hypertension.

2. Japanese.
Fewer variations in the pathophysiology of hypertension and/or a more homogeneous genetic and environmental background may explain why the results reported for Japanese populations are more uniform. The frequency of the T235 allele is invariably high in the Japanese population, ranging from 0.65 (112) to 0.75 (113). An association between hypertension and molecular variants of AGT in the Japanese population has been found in several independent studies. All the studies reported so far show that the AGT variant 235T is more frequent in essential hypertensives than in normotensive controls (112, 113, 114, 115), except for one study that found a higher frequency of the 174M allele in hypertensives than in normotensives (116). Another study found the TT genotype of the AGT gene was a predictor of blood pressure in a subpopulation less than 50 yr old within a total of 347 Japanese subjects (117).

3. African and Americans of African origin.
Hypertension is more prevalent and more severe in African and African-Americans than in Caucasians. The genetic factors that contribute to this ethnic difference are not known. These hypertensive populations tend to be sensitive to sodium and have low circulating renin concentrations. The 235T allele is by far the most frequent in Africans (0.90) and in African- Americans (0.80) (118), which is consistent with an approximate 25% admixture of genes of European origin in the African-Americans (99). A weak association between blood pressure and AGT has been found in a community survey in Jamaica, but the effect was more marked in conjunction with the plasma ACE concentration (119). The frequency of the M235T variant has been evaluated in several studies, but it is difficult to rule out an association of this allele with hypertension (98) because of the high prevalence of this allele in these populations.

The frequent occurrence of the 235T allele in most human populations and a thorough haplotype analysis of ten diallelic variants of the AGT gene (110) suggests that the 235T variant of AGT is the ancestral form and the 235M allele is the neomorph. This is of interest when examining the development of the renin-angiotensin system across species, as the way in which living creatures adapted to their salt environment, by maintaining blood pressure and sodium balance through vasoconstriction and salt retention (120). Hominids were probably almost exclusively vegetarians several million years ago; therefore their diet contained very little sodium and a large amount of potassium, which can be a strong selective environment. That selection pressure could have favored salt retention mechanisms that had developed earlier in phylogeny, resulting in the selection of alleles giving optimal salt reabsorption. Since the 235T allele is associated with elevated circulating AGT that could influence the activity of the renin-angiotensin system, the AGT 235T allele could be one of the genes that fostered increased sodium reabsorption and increased blood pressure.

D. Pregnancy-induced hypertension
The above studies all suggest that a susceptible allele of the AGT gene is associated with increases in the plasma AGT concentration and in blood pressure. This effect could be more marked in conditions in which the synthesis of AGT is stimulated, such as in patients receiving oral estrogen or in pregnancy. Clinical studies have documented a familial tendency to develop preeclampsia, and familial studies have suggested that there are both genetic and environmental factors involved (121, 122).

Two reports initially indicated that the AGT locus played an important part in pregnancy-induced hypertension. Ward et al. (123) found a significant association between the AGT M235T variant and preeclampsia in both Caucasian and Japanese patients. Arngrimsson et al. (124) analyzed the allelic inheritance of the GT repeat in 52 sibling pairs of preeclamptic sisters and found a significant linkage between the AGT locus and preeclampsia in Icelandic and Scottish families. A more recent case-control study on 139 Japanese women with pregnancy-induced hypertension and 278 matched controls found a significant association with the 235T variant (125). However, two other limited studies in Caucasian women found no indication of cosegregation or association between preeclampsia and an AGT allele (126, 127). Thus, although the mechanisms proposed for preeclampsia and essential hypertension are different, a frequent variant of the AGT gene could predispose subjects to both diseases.

E. M235T variants, plasma AGT concentration, and blood pressure
Several lines of evidence indicate that the plasma AGT concentration is linked to the blood pressure. A remarkably high correlation between the concentration of the renin substrate and elevated blood pressure (r = 0.39, P < 0.0001) was first reported in a large study involving 574 subjects (128). The plasma AGT was also found to be elevated in hypertensives and the offspring of hypertensive parents compared with normotensives (129). In a study designed to assess genetic determinants of blood pressure by comparing the offspring of parents having high or low blood pressures ("four-corners" approach), Watt et al. (130) found that offspring of hypertensive patients had elevated plasma AGT levels compared to offspring of normotensive parents. Two cases of hypertension associated with hepatic cell tumors producing large amounts of AGT have been reported (131, 132). The above findings suggest that an increase in plasma AGT might elevate blood pressure and contribute to human essential hypertension.

There is evidence that the AGT genotype has a moderate effect on the plasma AGT concentration, as plasma AGT is about 20% higher in subjects (both men and women) carrying the T235 allele (5, 101). The effect associated with M235T appears to be codominant in females (5). Bloem et al. (99) also found that the plasma AGT concentrations of normotensive white American children carrying the 235TT genotype were about 13% higher than those with the 235M genotype. The effect of genotype remained significant after adjustment for body mass index, since the plasma AGT was highly correlated with body mass index. The same authors found that the mean plasma AGT concentration in African-American children was 19% higher than in Caucasians, but the association was not detected because the frequency of M235 was too low to observe an association. Indeed, when splitting the 235T allele with another AGT gene polymorphism in African-Americans, Pratt and co-workers (133) found a significant association with plasma AGT levels. Busjahn et al. (134) recently reported a trend to a codominant effect of the 235T AGT allele on the plasma AGT concentration in twins, although the variation in the concentration was too great for significance. Another recent study on a large sample of the MONICA Augsburg cohort also found a mild codominant and a significant increase in plasma AGT concentration according to the M235T variant (111). Because of the intra- and interassay variations in the plasma AGT measurement, and because the M235T variant only causes a 10–30% increase in plasma AGT, a large number of individuals are probably required to detect this relationship.

F. Association of AGT variants with the renal blood flow response to Ang II infusion
Williams and Hollenberg (135) have shown in a series of studies that nonmodulation is a trait in which renal, vascular, and adrenal zona glomerulosa responsiveness to angiotensin II is not modulated by a high Na⁺ intake. Up to 40% of essential hypertensive patients may have this trait; they have a reduced renal vascular response to angiotensin II when on a high-salt diet. Nonmodulators could, therefore, be a discrete subset of the essential hypertension population. This trait seems to be genetically inherited (136). The same group recently showed that the renal vascular response to Ang II of homozygous patients carrying the 235T genotype was blunted to that of patients with the heterozygous or homozygous M235 genotype (137). Obesity was also found to interact significantly with genotype and enhance the blunting of the renal vascular response. These results are in agreement with those obtained with AGT knock-out mice (see below) and suggest that patients carrying the 235T genotype produce more intrarenal Ang II, thereby contributing to a disturbed renal physiology.

	VII. Molecular Genetics of AGT and Other Diseases

Top Abstract I. Introduction II. Structure of the... III. Characteristics of AGT IV. Tissue and Cellular... V. Regulation VI. Molecular Genetics of... VII. Molecular Genetics of... VIII. Effects of AGT... IX. Conclusions and Perspectives References

 
A. AGT variants and coronary heart disease
Several studies have evaluated the relative risk of cardiovascular diseases conferred by gene variants of the renin-angiotensin system. Cambien et al. (138) reported in the "Etude Cas-Témoin de l’Infarctus du Myocarde" (ECTIM) an association between variants of the ACE gene and myocardial infarction in Caucasian patients considered at little risk of cardiovascular diseases according to their lipid profile and body mass index. The same case and control populations (630 patients who survived a myocardial infarction and 741 controls) were used to explore the role of the M235T and T174M AGT gene variants in the pathogenesis of coronary disease. Although they found no difference in the AGT genotype distributions in the cases and controls (139), carriers of the M174 allele were more often receiving antihypertensive treatment, and a greater proportion of them required several drugs. Three other studies have shown an association between the M235T AGT allele and coronary heart disease. A limited case-control study (82 cases and 160 controls) by Ishigami et al. (140) found a marginally higher frequency of the 235T allele in Japanese patients with coronary atherosclerosis (at least one coronary artery with more than 25% luminal diameter reduction); Katsuya et al. (141) reported that a group of 422 patients from New Zealand were at greater risk of coronary heart disease than were 406 matched controls: the 235T allele increased the risk of CHD 2- to 6-fold and the risk of myocardial infarction 3- to 4-fold, after adjustment for several other risk factors. Finally, Kamitani et al. (142) found that the 235TT genotype was more frequent in Japanese patients with myocardial infarction than in a control group and that the odds ratio for this genotype was further increased in patients carrying the ACE DD genotype. However, another large study designed to detect an association between variants in the renin-angiotensin system genes and the degree of coronary artery stenosis in Caucasians revealed no correlation with the ACE I/D polymorphism and M235T variants (143).

B. AGT variants and complications of diabetes
Degenerative retinopathy and nephropathy are frequent complications of insulin-dependent diabetes mellitus (IDDM). Several factors, such as the duration of IDDM, blood glucose control, and genetic factors, influence these complications. The genes of the renin-angiotensin system, in particular ACE (144, 145), may be implicated in diabetic nephropathy, since high glomerular concentrations of angiotensin II can favor glomerular hypertension and contribute to renal deterioration.

The relationship between AGT variants and diabetic nephropathy in patients with IDDM has been evaluated recently. A large study on Caucasian IDDM patients with (n = 195 patients) or without (n = 185 patients) nephropathy, who had been diabetic for about 26 yr found no difference in the M235T genotype distributions in the two groups (146). The patients with nephropathy who were homozygous for the 235T allele had a higher systolic blood pressure than those carrying the T235 M or the M235 M genotype. Similarly, another study on 380 patients who had had IDDM for 15–20 yr found that the 235T allele did not appear to increase susceptibility to nephropathy (147), although the 235T allele was more frequent among normotensive and hypertensive patients with microalbuminuria than in patients with normoalbuminuria. Another study on 423 Caucasian patients with type 1 diabetes and 663 with type 2 diabetes was also negative (148).

The absence of any association between the M235T variant and diabetic nephropathy does not definitively exclude a role for the AGT gene in this situation. A recent report found a positive correlation between the 235T variant and diabetic nephropathy in Irish patients with IDDM (149). The contributing effect of the M235T variant could be too small to be detected in most of the studies performed so far. A more recent study on 494 Caucasian IDDM patients found that the severity of renal involvement was associated with the ACE I/D variant (150). There was also a positive interaction between the ACE I/D and AGT M235T variants, suggesting that patients with both the ACE D and AGT 235T alleles were more at risk of developing nephropathy.

C. AGT, obesity, and blood pressure
AGT is quite abundant in adipose tissue, and the local synthesis of AGT could be part of a paracrine system influencing the release of Ang II in the vicinity of the vascular smooth muscle cells. A person’s nutritional status could influence the blood supply to adipose tissue and thus affect vascular resistance and blood pressure in obese individuals. The plasma AGT concentration is in fact strongly correlated with blood pressure during weight loss (151). A study of 67 obese Japanese women showed that those who were hypertensive had a higher intraabdominal/subcutaneous fat index than the normotensives (152). The same study showed a strong significant correlation between this fat index and systolic (r = 0.62) and diastolic (r = 0.63) blood pressures, regardless of age or body mass index. The association between intraabdominal fat accumulation and hypertension raises the question of whether AGT is involved in the pathogenesis of hypertension in obese individuals. The previously mentioned ECTIM study (139) found that the M174T AGT variant was associated with hypertension only in lean individuals. Subjects with body mass index less than 26 kg/m² who carried the M174 allele were 2–4 times more likely to have high blood pressure than homozygotes for the T174 allele, whereas there was no association in subjects with a body mass index greater than 26 kg/m². These results suggest that the production and regulation of AGT in adipose tissue interact with blood pressure.

	VIII. Effects of AGT Gene Variants and Gene Targeting on Ang I Production and Blood Pressure

Top Abstract I. Introduction II. Structure of the... III. Characteristics of AGT IV. Tissue and Cellular... V. Regulation VI. Molecular Genetics of... VII. Molecular Genetics of... VIII. Effects of AGT... IX. Conclusions and Perspectives References

 
The evidence incriminating AGT in human hypertension remains statistical and raises the question of whether the 235T AGT allele is itself functional or whether it is a marker of another closely linked variant. Other approaches are, therefore, needed to describe the precise influence of AGT on Ang production and blood pressure control.

A. Human studies
Two rare missense mutations of the AGT gene have been described recently. These provide a unique opportunity to study in vitro and in vivo the consequences of these modifications of the AGT protein structure (Fig. 3). A mutation at the site (Leu₁₀-Val₁₁) where AGT is cleaved by renin was recently found in a patient with preeclampsia (153): a phenylalanine residue replaced the leucine residue. This resulted in a 2-fold increase in the catalytic efficiency of the renin acting on the corresponding human mutated AGT produced by transient expression. ACE also had more than a 2-fold greater catalytic efficiency for the angiotensin decapeptide with phenylalanine at residue 10 than for natural Ang I. These kinetic differences may significantly affect the production of Ang II and alter the function of the systemic or local renin systems in this form of pregnancy-induced hypertension. The same mutation has also been found in two other unrelated hypertensive patients screened for variants of AGT because of a severe and familial form of hypertension. The wild type Ang I and the mutated Ang I (Ang I-Phe₁₀) were measured separately by specific RIAs in one affected patient. The basal and captopril-stimulated plasma concentrations of Ang I-Phe₁₀ were elevated, showing increased production of angiotensin from the mutated AGT allele (X. Jeunemaitre, T. Guyene, M. Azizi, J. Menard, and P. Corvol, unpublished).

View larger version (9K): [in this window] [in a new window]   Figure 3. Polymorphisms of the promoter region of the human AGT gene. The three polymorphisms are in strong linkage disequilibrium with M235T. The G-6A substitution has been found to be associated with an increased AGT expression. [Derived from X. Jeunemaitre et al. (5); K. Yanai et al. (86), and I. Inoue (87).]

There is no evidence that the common 235T variant directly affects the function, secretion, or metabolism of AGT, although the replacement of a methionine by a threonine residue is not neutral. Cohen et al. (155) used multiple monoclonal antibodies and two immunometric assays to show that there was an epitopic change that allowed plasma samples homozygous and heterozygous for this allele to be readily discriminated. However, the plasma AGT 235T variant had the same K_m for renin as AGT 235M (T. Guyene, J. Menard, and P. Corvol, unpublished results).

The 235T variant could be a marker for a putative, as yet unknown, molecular variant(s) that directly mediate predisposition to hypertension. Haplotypes have been generated in a large number of hypertensive French and Japanese subjects to resolve this question (110). Both groups had an AGT gene with a G A substitution at position -6 upstream of the initial transcription site, which was found to be in almost complete linkage disequilibrium with the 235T allele (Fig. 4). Tests of promoter activity and DNA binding studies with nuclear proteins from a human hepatoma cell line showed that this nucleotide substitution may be the functional variant, as it affects the basal transcription rate of AGT, which could explain the association of the M235T variant with the plasma AGT concentration (87).

View larger version (7K): [in this window] [in a new window]   Figure 4. Linkage disequilibrium between the M235T polymorphism in exon 2 of the AGT gene and the G(-6)A polymorphism in the promoter region of the gene.

C. Genetic hypertension in rats
Lodwick et al. (156) showed a cosegregation of the rat AGT locus with a specific, modest increase in pulse pressure in F2 rats derived from a cross between spontaneously hypertensive rats (SHR) and normotensive Wistar Kyoto rats (WKY). This locus accounted for approximately 20% of the genetic variance in this phenotype. The sequences of the AGT mRNA and plasma AGT protein in hypertensive and normotensive rats were similar, but the AGT mRNA concentrations of the two strains were different. It has also been reported that the AGT gene locus does not cosegregate with blood pressure in F2 rats derived from a cross between stroke-prone spontaneously hypertensive (SHR-SP) and WKY rats (157) and that there is a missense mutation in the SHR-SP AGT gene (158). Thus, the findings in SHR and SHR-SP appear to differ from those in humans. There are also differences in a number of high blood pressure loci identified in hypertensive rats that are not linked to hypertension in humans, such as the renin gene (93, 159) and the SA locus (160, 161). Clearly, disease-relevant genetic loci are not necessarily the same in man and rats.

D. Antisense AGT oligodeoxynucleotides
The role of AGT in regulating blood pressure in rats has also been recently evaluated using antisense oligodeoxynucleotides targeted at AGT mRNA. Pedrazzini et al. (162) generated a transgenic mouse line carrying an inducible antisense AGT gene, and showed a transient decrease in AGT synthesis in these animals. Injection of liposome-encapsulated antisense AGT oligodeoxynucleotides decrease plasma Ang II and blood pressure in SHR (163, 164).

E. Transgenic animals
The role of AGT in blood pressure regulation can also be explored by creating transgenic animals that overproduce AGT. One difficulty lies in the species specificity of the renin AGT reaction. Rat renin hydrolyzes a Leu-Leu bond in rat AGT, in constrast to the Leu-Val bond in human AGT. Because of this species specificity, mice or rats producing human renin or human AGT do not develop hypertension. Kimura et al. (165) generated transgenic mice that contained the entire rat AGT gene including 1.6 kb of 5'-flanking sequence. These animals developed hypertension, especially the males, and AGT was overproduced in the liver and brain. The synthesis of AGT in the brain seemed to be a prerequisite for the development of a hypertensive phenotype. Other transgenic animals have been generated by Ohkubo et al. (166), who introduced the rat renin gene, the rat AGT gene, or both into mice. The genes were under the control of the mouse metallothionine I gene promoter. A similar chimeric renin-angiotensin system was constructed by cross-mating separate lines of transgenic mice carrying either the human renin or AGT genes (167). Both models showed captopril-sensitive hypertension only in the transgenic mice carrying both transgenes. These experiments show the species specificity of the renin-AGT reaction in vivo confirming the in vitro findings (168). Although these transgenic experiments clearly demonstrate that overexpression of the renin and AGT genes leads to increased blood pressure, their relevance to the pathogenesis of human hypertension is questionable.

An interesting model of hypertension in pregnant mice has been recently reported: Takimoto et al. (169) observed that transgenic female mice producing human AGT developed a transient elevation in blood pressure in late pregnancy when they were mated with transgenic males producing human renin. Blood pressure returned to normal after delivery, renal histology showed glomerulopathy lesions, and the placenta was very abnormal. These abnormalities are also found in human pregnancy-induced hypertension. However, this result was not observed with the reverse combination of female renin transgenic mice and male AGT transgenic mice. This combination produced pups that were hypertensive, but no hypertension developed in the mothers, indicating the role of placental renin in the development of maternal hyper-tension.

F. AGT gene duplication
Finally, a fourth approach has been used by Smithies and co-workers (170, 171) to quantitatively evaluate the possibility that genetically determined elevated AGT concentrations are a predisposing factor for hypertension. The original strategy was to engineer mice having genetically determined high plasma concentrations of AGT, thereby mimicking the increased plasma AGT in familial hypertension. Targeted gene disruption and duplication were used to generate mice having one, two, three, or four copies of the AGT gene. Plasma AGT increased progessively, but not linearly, with the AGT gene copy number. The one-copy animals had plasma AGT concentrations that were about 35% of the normal value, and the three-copy animals had concentrations that were 124% of normal. Blood pressure also increased with the copy number; it was approximately 122 for the one-copy mice, 129 for the two-copy (wild type) mice, and 138 mm Hg for the three-copy animals (171). Renal blood flow varied inversely as the number of AGT copies. These results demonstrate directly that small increases in plasma AGT, of the same order of magnitude as those associated with the human AGT M235T variant, can influence the fine control of renal vascular resistance and blood pressure. These elegant studies also show that varying the number of copies of genes is probably the best way of assessing the roles of genes in a complex quantitative trait, such as high blood pressure.

	IX. Conclusions and Perspectives

Top Abstract I. Introduction II. Structure of the... III. Characteristics of AGT IV. Tissue and Cellular... V. Regulation VI. Molecular Genetics of... VII. Molecular Genetics of... VIII. Effects of AGT... IX. Conclusions and Perspectives References

 
AGT has long been considered to be simply a plasma "reservoir" upon which renin acts. The molecular genetic studies reviewed here strongly suggest that the AGT locus is involved in essential hypertension and also in some cases of pregnancy-induced hypertension. Experimental data from transgenic rodents and targeted AGT mice that have allowed the effect of the AGT gene to be quantified also support the human data. The results indicate that a molecular variant of AGT (235T/-6A) is associated with an increased rate of AGT gene transcription, which could result, in turn, in small increases in plasma and tissue AGT concentrations. Because the plasma, and especially the tissue, AGT concentration is rate limiting for Ang II generation, this genetically chronic overstimulation of the renin system favors kidney sodium reabsorption by the kidney, vascular hypertrophy and(or) increased sympathetic nervous system activity and predisposes the carrier to the development of common cardiovascular diseases. This effect may be more marked in the presence of other predisposing genes and/or deleterious environmental factors.

The role of AGT in hypertension and cardiovascular diseases can be summarized as follows:

1. AGT variants appear to have a modest effect on blood pressure in the whole population, which probably explains some of the positive and negative findings with the M235T variant. The percentage of hypertension attributable to AGT is difficult to quantify but does not appear to exceed approximately 10%. The relative risk of cardiovascular disease conferred by this gene is probably not greater than 20–30%.

2. The effect of AGT variants is probably modulated by a variety of interacting genes, such as the ACE gene (109), and environmental factors such as salt intake and obesity. This type of susceptibility allele will only be useful if it results in a great relative risk of developing hypertension. Thus, defining the subset of individuals in whom it may play a more important role, such as pregnancy-induced hypertension, will be one of the important tasks for the near future.

3. Local increases in AGT in tissues involved in blood pressure regulation (such as the kidney and the brain) may well be important for Ang II generation. This will have to be investigated in patients with different AGT genotypes. The small increase in plasma AGT should have only a minor effect on Ang II generation and should be counteracted by the negative feedback of this peptide on renin secretion.

4. The response to antihypertensive agents, especially those that block the renin system, needs to be evaluated in patients classified according to their genotype. A preliminary investigation on a limited number of hypertensive patients classified according to their AGT or ACE phenotypes (172) provided no evidence for such association. Large, prospective studies, with randomization of patients according to their genotype, are needed to obtain meaningful information.

	Acknowledgments

 
The English text was checked by Dr. Owen Parkes.

	Footnotes

 
Address reprint requests to: P. Corvol, M.D., INSERM U36, 3 rue d’Ulm, 75005 Paris, France.

¹ This work was supported by Grants from INSERM, the Collège de France, Bristol-Myers Squibb, the Association Claude Bernard, and the Association Naturalia and Biologia.

	References

Top Abstract I. Introduction II. Structure of the... III. Characteristics of AGT IV. Tissue and Cellular... V. Regulation VI. Molecular Genetics of... VII. Molecular Genetics of... VIII. Effects of AGT... IX. Conclusions and Perspectives References

 

1. Ward R 1990 Familial aggregation and genetic epidemiology of blood pressure. In: Laragh JH, Brenner BM (eds) Hypertension: Pathophysiology, Diagnosis and Management. Raven Press Ltd, New York, pp 81–100
2. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel J-M 1992 A chimaeric 11ß-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355:262–265[CrossRef][Medline]
3. Shimkets RA, Warnock DG, Bositis CM, Nelson-Williams C, Hansson JH, Shambelan M, Gill JJ, Ulick S, Milora RV, Findling JW, Canessa C, Rossier BC, Lifton RP 1994 Liddle’s syndrome: heritable human hypertension caused by mutations in the ß subunit of the epithelial sodium channel. Cell 79:407–414[CrossRef][Medline]
4. Mune T, Rogerson FM, Nikkila H, Agarwal AK, White PC 1995 Human hypertension caused by mutations in the kidney isozyme of 11ß-hydroxysteroid dehydrogenase. Nat Genet 10:394–399[CrossRef][Medline]
5. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, Hunt SC, Hopkins PN, Williams RR, Lalouel J-M, Corvol P 1992 Molecular basis of human hypertension. Role of angiotensinogen. Cell 71:169–180[CrossRef][Medline]
6. Kageyama R, Ohkubo H, Nakanishi S 1984 Primary structure of human preangiotensinogen deduced from the cloned cDNA sequence. Biochemistry 23:3603–3609[CrossRef][Medline]
7. Gaillard I, Clauser E, Corvol P 1989 Structure of human angiotensinogen gene. DNA 8:87–99[Medline]
8. Isa MN, Boyd E, Morrison N, Harrap E, Clauser E, Connor JM 1990 Assignment of the human angiotensinogen gene to chromosome 1q42–q43 by nonisotopic in situ hybridization. Genomics 8:598–600 [published erratum appears in Genomics 1991,10:1110][CrossRef][Medline]
9. Gaillard-Sanchez I, Mattei MG, Clauser E, Corvol P 1990 Assignment by in situ hybridization of the angiotensinogen gene to chromosome band 1q42, the same region as human renin gene. Hum Genet 84:341–343[Medline]
10. Jeunemaitre X, Lifton RP 1993 Genes of the renin angiotensin system and the genetics of human hypertension. In: Raizada MK, Phillips MI, Sumners C (eds) Cellular and Molecular Biology of the Renin Angiotensin System. CRC Press, Boca Raton, FL, pp 73–94
11. Kotelevtsev YV, Clauser E, Corvol P, Soubrier F 1991 Dinucleotide repeat polymorphism in the human angiotensinogen gene. Nucleic Acids Res 19:6978[Free Full Text]
12. Dracopoli NC, O’Connell P, Elsner TI, Lalouel J-M, White RL, Buetow KH, Nishimura DY, Murray JC, Helms C, Mishra SK, Donis-Keller H, Hall JM, Lee MK, King M-C, Attwood J, Morton NE, Robson E, Mahtani M, Willard HF, Royle NJ, Patel I, Jeffreys AJ, Verga V, Jenkins T, Weber JL, Mitchell AL, Bale AE 1991 The CEPH consortium linkage map of human chromosome 1. Genomics 9:686–700
13. Clouston WM, Evans BA, Haralambidis J, Richards RI 1988 Molecular cloning of the mouse angiotensinogen gene. Genomics 2:240–248[CrossRef][Medline]
14. Chirgwin JM, Schaefer IM, Diaz JA, Lalley PA 1984 Mouse kidney renin gene is on chromosome 1. Som Cell Mol Genet 10:633–637[CrossRef][Medline]
15. Mori M, Ishizaki K, Yamada T, Chen H, Sugiyama T, Serikawa T, Yamada J 1989 Restriction fragment length polymorphisms of the angiotensinogen gene in inbred rat strains and mapping of the gene on chromosome 19q. Cytogenet Cell Genet 50:42–45[Medline]
16. Pravenec M, Simonet L, Kren V, Kunes J, Levan G, Szpirer J, Szpirer C, Kurtz T 1991 The rat renin gene: assignment to chromosome 13 and linkage to the regulation of blood pressure. Genomics 9:466–472[CrossRef][Medline]
17. Hilgenfeldt U 1988 Half-life of rat angiotensinogen: influence of nephrectomy and lipopolysaccharide stimulation. Mol Cell Endocrinol 56:91–98[CrossRef][Medline]
18. Tewksbury DA, Dart RA 1982 High molecular weight angiotensinogen levels in hypertensive pregnant women. Hypertension 4:729–734[Abstract/Free Full Text]
19. Oxvig C, Haaning J, Kristensen L, Wagner JM, Rubin I, Stigbrand T, Gleich GJ, Sottrup-Jensen L 1995 Identification of angiotensinogen and complement C3dg as novel proteins binding the proform of eosinophil major basic protein in human pregnancy serum and plasma. J Biol Chem 270:13645–13651[Abstract/Free Full Text]
20. Genain C, Bouhnik J, Tewksbury D, Corvol P, Ménard J 1984 Characterization of plasma and cerebrospinal fluid human angiotensinogen and des-angiotensin I angiotensinogen by direct radioimmunoassay. J Clin Endocrinol Metab 59:478–484[Abstract/Free Full Text]
21. Bouhnik J, Clauser E, Gardes J, Corvol P, Ménard J 1982 Direct radioimmunoassay of rat angiotensinogen and its application to rats in various endocrine states. Clin Sci 62:355–360[Medline]
22. Ito T, Eggena P, Barrett JD, Katz D, Metter J, Sambhi MP 1980 Studies on angiotensinogen of plasma and cerebrospinal fluid in normal and hypertensive human subjects. Hypertension 2:432–436[Abstract/Free Full Text]
23. Tewksbury DA 1990 Angiotensinogen: biochemistry and molecular biology. In: Laragh JJ, Brenner BM (eds) Hypertension, Pathophysiology, Diagnosis and Management. Raven Press Publishers, New York, vol 1:1197–1216
24. Cumin F, N’Guyen D, Castro B, Ménard J, Corvol P 1987 Comparative enzymatic studies of human renin acting on pure natural or synthetic substrates. Biochim Biophys Acta 913:10–19[CrossRef][Medline]
25. Gardes J, Bouhnik J, Clauser E, Corvol P, Ménard J 1982 Role of angiotensinogen in blood pressure homeostasis. Hypertension 4:185–189[Abstract/Free Full Text]
26. Ménard J, El-Amrani AIK, Savoie F, Bouhnik J 1991 Angiotensinogen: an attractive and underrated participant in hypertension and inflammation. Hypertension 18:705–706[Free Full Text]
27. Tanaka T, Ohkubo H, Nakanishi S 1984 Common structural organization of the angiotensinogen and the 1-antitrypsin genes. J Biol Chem 259:8063–8065[Abstract/Free Full Text]
28. Doolittle RF 1983 Angiotensinogen is related to the antitrypsin-antithrombin-ovalbumin family. Science 222:417–419[Abstract/Free Full Text]
29. Bing J 1972 Relation between renin substrate and acute phase proteins. Studies of normal and adrenalectomized rats. Acta Pathol Microbiol Scand [A] 80:646–650[Medline]
30. Kageyama R, Ohkubo H, Nakanishi S 1985 Induction of rat liver angiotensinogen mRNA following acute inflammation. Biochem Biophys Res Commun 129:826–832[CrossRef][Medline]
31. Bouhnik J, Savoie F, Corvol P 1988 Differential effects of inflammation models on rat T-kininogen and rat-angiotensinogen. Biochem Pharmacol 37:1099–1102[CrossRef][Medline]
32. Nielsen AHJ, Knudsen F 1987 Angiotensinogen is an acute-phase protein in man. Scand J Clin Lab Invest 47:175–178[Medline]
33. Stock P, Liefeldt L, Paul M, Ganten D 1995 Local renin-angiotensin systems in cardiovascular tissues: localization and functional role. Cardiology 86:2–8
34. Campbell DJ 1987 Circulating and tissue angiotensin systems. J Clin Invest 79:1–6
35. Campbell DJ, Habener JF 1986 Angiotensinogen gene is expressed and differentially regulated in multiple tissues of the rat. J Clin Invest 78:31–39
36. Phillips MI, Speakman EA, Kimura B 1993 Tissue renin-angiotensin system. In: Raidaza MK, Phillips MI, Summers C (eds) Cellular and Molecular Biology of the Renin-Angiotensin System. CRC Press, Boca Raton, FL, pp 97–130
37. Dzau VJ, Ellison KE, Brody T, Ingelfinger J, Pratt RE 1987 A comparative study of the distributions of renin and angiotensinogen messenger ribonucleic acids in rat and mouse tissues. Endocrinology 120:2334–2338[Abstract/Free Full Text]
38. Lynch KR, Simnad VI, Ben-Ari ET, Garrison JC 1986 Localization of preangiotensinogen messenger RNA sequences in the rat brain. Hypertension 8:540–543[Abstract/Free Full Text]
39. Stornetta RL, Hawelu-Johnson CL, Guyenet PG, Lynch KR 1988 Astrocytes synthesize angiotensinogen in brain. Science 242:1444–1446[Abstract/Free Full Text]
40. Bunnemann B, Fuxe K, Ganten D 1993 The renin-angiotensin system in the brain: an update 1993. Regul Pept 46:487–509[CrossRef][Medline]
41. Milsted A, Barna BP, Ransohoff RM, Brosnihan KB, Ferrario CM 1990 Astrocyte cultures derived from human brain tissue express angiotensinogen mRNA. Proc Natl Acad Sci USA 87:5720–5723[Abstract/Free Full Text]
42. Deschepper CF, Bouhnik J, Ganong WF 1986 Colocalization of angiotensinogen and glial fibrillary acidic protein in astrocytes in rat brain. Brain Res 374:195–198[CrossRef][Medline]
43. Campbell DJ, Habener JF 1987 Cellular localization of angiotensinogen gene expression in brown adipose tissue and mesentery: quantification of messenger ribonucleic acid abundance using hybridization in situ. Endocrinology 121:1616–1626[Abstract/Free Full Text]
44. Ohkubo H, Nakayama K, Tanaka T, Nakanishi S 1986 Tissue distribution of rat angiotensinogen mRNA and structural analysis of its heterogeneity. J Biol Chem 261:319–323[Abstract/Free Full Text]
45. Naftilan AJ, Zuo WM, Ingelfinger JR, Ryan TJJ, Pratt RE, Dzau VJ 1991 Localization and differential regulation of angiotensinogen mRNA expression in the vessel wall. J Clin Invest 87:1300–1311
46. Cassis LA, Saye J, Peach MJ 1988 Location and regulation of rat angiotensinogen messenger RNA. Hypertension 11:591–596[Abstract/Free Full Text]
47. Hilgers KF, Hilgenfeldt U, Veelken R, Muley T, Ganten D, Luft FC, Mann JFE 1993 Angiotensinogen is cleaved to angiotensin in isolated rat blood vessels. Hypertension 21:1030–1034[Abstract/Free Full Text]
48. Lindpaintner K, Jin MW, Niedermaier N, Wilhelm MJ, Ganten D 1990 Cardiac angiotensinogen and its local activation in the isolated perfused beating heart. Circ Res 67:564–573[Abstract/Free Full Text]
49. Dzau VJ 1988 Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 77 [Suppl I]:I4–I13
50. Fried TA, Simpson EA 1986 Intrarenal localization of angiotensinogen mRNA by RNA-DNA dot-blot hybridization. Am J Physiol 250:F374–F377
51. Ingelfinger JR, Zuo WM, Fon EA, Ellison KE, Dzau VJ 1990 In situ hybridization evidence for angiotensinogen messenger RNA in the rat proximal tubule. An hypothesis for the intrarenal renin angiotensin system. J Clin Invest 85:417–423
52. Ingelfinger JR, Pratt RE, Ellison K, Dzau VJ 1986 Sodium regulation of angiotensinogen mRNA expression in rat kidney cortex and medulla. J Clin Invest 78:1311–1315
53. Misumi J, Gardes J, Gonzales M-F, Corvol P, Ménard J 1989 Angiotensinogen’s role in angiotensin formation, renin release, and renal hemodynamics in isolated perfused kidney. Am J Physiol 256:F719–F727
54. Saye JA, Lynch KR, Peach MJ 1990 Changes in angiotensinogen messenger RNA in differentiating 3T3–F442A adipocytes. Hypertension 15:867–871[Abstract/Free Full Text]
55. Darimont C, Vassaux G, Gaillard D, Ailhaud G, Negrel R 1994 In situ microdialysis of prostaglandins in adipose tissue: stimulation of prostacyclin release by angiotensin II. Int J Obes Relat Metab Disord 18:783–788[Medline]
56. Frederich Jr RC, Kahn BB, Peach MJ, Flier JS 1992 Tissue-specific nutritional regulation of angiotensinogen in adipose tissue. Hypertension 19:339–344[Abstract/Free Full Text]
57. Harp JB, Di Girolamo M 1995 Components of the renin-angiotensin system in adipose tissue: changes with maturation and adipose mass enlargement. J Gerontol A Biol Sci Med 50:B270–B276
58. Racz K, Pinet F, Gasc J-M, Guyene T-T, Corvol P 1992 Coexpression of renin, angiotensinogen and their messenger ribonucleic acids in adrenal tissues. J Clin Endocrinol Metab 75:730–737[Abstract]
59. Mulrow PJ 1992 Adrenal renin: regulation and function. Front Neuroendocrinol 13:47–60[Medline]
60. Robertson JIS 1993 Angiotensinogen measurement. In: Roberston JIS, Nicholls MG (eds) The Renin Angiotensin System, Biochemistry - Physiology. Gower Medical Publishing, London, vol 14:1–8
61. Lynch KR, Peach MJ 1991 Molecular biology of angiotensinogen. Hypertension 17:263–269[Free Full Text]
62. Deschepper CF, Hong-Brown LQ 1993 Hormonal regulation of the angiotensinogen gene in liver and other tissues In: Raizada MK, Philips MI, Sumners C (eds) Cellular and Molecular Biology of the Renin Angiotensin System. CRC Press, Boca Raton, FL, pp 149–166
63. Kunapuli SP, Benedict CR, Kumar A 1987 Tissue specific hormonal regulation of the rat angiotensinogen gene expression. Arch Biochem Biophys 254:642–646[CrossRef][Medline]
64. Nakamura A, Iwao H, Fukui K, Kimura S, Tamaki T, Nakanishi S, Abe Y 1990 Regulation of liver angiotensinogen and kidney renin mRNA levels by angiotensin II. Am J Physiol 258:E1–E6
65. Chang E, Perlman AJ 1987 Multiple hormones regulate angiotensinogen messenger ribonucleic acid levels in a rat hepatoma cell line. Endocrinology 121:513–519[Abstract/Free Full Text]
66. Brasier AR, Philippe J, Campbell DJ, Habener JF 1986 Novel expression of the angiotensinogen gene in a rat pancreatic islet cell line. Transcriptional regulation by glucocorticoids. J Biol Chem 261:16148–16154[Abstract/Free Full Text]
67. Gahnem F, Camargo MJ, von Lutterotti N, Laragh JH, Sealey JE 1995 Angiotensinogen depletion by high renin levels in hypertensive rats: no evidence for tonic stimulation of angiotensinogen by angiotensin II. J Hypertens 13:96–96
68. Jaramillo HN, Sambhi MP, Bouhnik J, Corvol P, Ménard J 1987 Liver angiotensinogen synthesis and release during captopril treatment in sodium-depleted rats. Endocrinology 120:1384–1390[Abstract/Free Full Text]
69. Skinner SL, Lumbers ER, Symonds EM 1972 Analysis of changes in the renin-angiotensin system during pregnancy. Clin Sci 42:479–488[Medline]
70. Derkx FH, Steunkel C, Schalekamp MP, Visser W, Huisveld IH, Schalekamp MA 1986 Immunoreactive renin, prorenin, and enzymatically active renin in plasma during pregnancy and in women taking oral contraceptives. J Clin Endocrinol Metab 63:1008–1015[Abstract/Free Full Text]
71. Hollenberg NK, Williams GH, Burger B, Chenitz W, Hoosmand I, Adams DF 1976 Renal blood flow and its response to angiotensin II. An interaction between oral contraceptive agents, sodium intake, and the renin-angiotensin system in healthy young women. Circ Res 38:35–40[Abstract/Free Full Text]
72. DeLignieres B, Basdevant A, Thomas G, Thalabard J-C, Mercier-Bodard C, Conard J, Guyene T-T, Mairon N, Corvol P, Guy-Grand B, Mauvais-Jarvis P, Sitruk-Ware R 1986 Biological effects of estradiol-17ß in postmenopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab 62:536–541[Abstract/Free Full Text]
73. Laragh JH, Sealey JE, Ledingham JGG, Newton MA 1967 Oral contraceptives. Renin, aldosterone and high blood pressure. JAMA 201:918–922[Abstract/Free Full Text]
74. Krakoff LR, Einsenfeld AJ 1977 Hormonal control of plasma renin substrate (angiotensinogen). Circ Res 41:II-43-II-46
75. Weir RJ, Fraser R, McElwee G, Morton JJ, Tree M, Young J 1974 The effect of estrogen-progestogen oral contraceptives on blood pressure and on the renin-angiotensin-aldosterone system. In: Fregly MJ, Fregly MS (eds) Oral Contraceptives and High Blood Pressure. Dolphin Press, Gainesville, FL, pp 68–75
76. Campbell DJ, Lawrence AC, Towrie A, Kladis A, Valentijn AJ 1991 Differential regulation of angiotensin peptide levels in plasma and kidney of the rat. Hypertension 18:763–773[Abstract/Free Full Text]
77. Hilgenfeldt U, Schott R 1987 Differences in pattern of plasma angiotensinogen in native and nephrectomized rats. Hypertension 9:339–344[Abstract/Free Full Text]
78. Eggena P, Barrett JD 1992 Regulation and functional consequences of angiotensinogen gene expression. J Hypertens 10:1307–1311[CrossRef][Medline]
79. Soden M, Klett C, Hasmann T, Hackenthal E 1994 Angiotensinogen: an acute-phase protein? Hypertension 23:I126–I130
80. Rakugi H, Jacob HJ, Krieger JE, Ingelfinger JR, Pratt RE 1993 Vascular injury induces angiotensinogen gene expression in the media and neointima. Circulation 87:283–290[Abstract/Free Full Text]
81. Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein CS, Lorell BH 1990 Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation. J Clin Invest 86:1913–1930
82. Schunkert H, Ingelfinger JR, Hirsch AT, Tang SS, Litwin SE, Talsness CE, Dzau VJ 1992 Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure. J Clin Invest 90:1523–1529
83. Klett C, Hellmann W, Müller F, Suzuki F, Nakanishi S, Ohkubo H, Ganten D, Hackenthal E 1988 Angiotensin II controls angiotensinogen secretion at a pretranslational level. J Hypertens 6 [Suppl 4]:S442–S445
84. Brasier AR, Li J 1996 Mechanisms for inducible control of angiotensinogen gene transcription. Hypertension 27 [part 2]:465–475
85. Tamura K, Umemura S, Ishii M, Tanimoto K, Murakami K, Fukamizu A 1994 Molecular mechanism of transcriptional activation of angiotensinogen gene by proximal promoter. J Clin Invest 93:1370–1379
86. Yanai K, Nibu Y, Murakami K, Fukamizu A 1996 A cis-acting DNA element located between TATA box and transcription initiation site is critical in response to regulatory sequences in human angiotensinogen gene. J Biol Chem 271:15981–15986[Abstract/Free Full Text]
87. Inoue I, Nakajima T, Williams CS, Quackenbush J, Puryear R, Powers M, Cheng T, Ludwig EH, Sharma AM, Hata A, Jeunemaitre X, Lalouel J-M 1997 A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 99:1786–1797[Medline]
88. Lander ES, Schork NJ 1994 Genetic dissection of complex traits. Science 265:2037–2048[Abstract/Free Full Text]
89. Risch N, Zhang H 1995 Extreme discordant sib pairs for maping quantitative trait loci in humans. Science 268:1584–1589[Abstract/Free Full Text]
90. Risch N, Merikangas K 1996 The future of genetic studies of complex human diseases. Science 273:1516–1517[Abstract/Free Full Text]
91. Falk CT, Rubinstein P 1987 Haplotype relative risks: an easy reliable way to construct a proper control sample for risk calculations. Ann Hum Genet 51:227–233[Medline]
92. Spielman RS, McGinnis RE, Ewens WJ 1993 Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am J Hum Genet 52:506–516[Medline]
93. Jeunemaitre X, Rigat B, Charru A, Houot A-M, Soubrier F, Corvol P 1992 Sib pair linkage analysis of renin gene haplotypes in human essential hypertension. Hum Genet 88:301–306[Medline]
94. Jeunemaitre X, Lifton RP, Hunt SC, Williams RR, Lalouel J-M 1992 Absence of linkage between the angiotensin converting enzyme locus and human essential hypertension. Nat Genet 1:72–75[CrossRef][Medline]
95. Bonnardeaux A, Davies A, Jeunemaitre X, Fery I, Charru A, Clauser E, Tiret L, Cambien F, Corvol P, Soubrier F 1994 Angiotensin II type 1 receptor gene polymorphism in human essential hypertension. Hypertension 24:63–69[Abstract/Free Full Text]
96. Caulfield M, Lavender P, Farrall M, Munroe P, Lawson M, Turner P, Clark AJ 1994 Linkage of the angiotensinogen gene to essential hypertension. N Engl J Med 330:1629–1633[Abstract/Free Full Text]
97. Caulfield M, Lavender P, Newell-Price J, Farrall M, Kamdar S, Daniel H, Lawson M, De Freitas P, Fogarty P, Clark AJ 1995 Linkage of the angiotensinogen gene locus to human essential hypertension in African Caribbeans. J Clin Invest 96:687–692
98. Rotimi C, Morrisson L, Cooper R, Oyejide C, Effiong E, Ladipo M, Osotemihen B, Ward R 1994 Angiotensinogen gene in human hypertension. Lack of an association of the 235T allele among African Americans. Hypertension 24:591–594[Abstract/Free Full Text]
99. Bloem LJ, Manatunga AK, Tewksbury DA, Pratt JH 1995 The serum angiotensinogen concentration and variants of the angiotensinogen gene in white and black children. J Clin Invest 95:948–953
100. Bennett CL, Schrader AP, Morris BJ 1993 Cross-sectional analysis of Met235Thr variant of angiotensinogen gene in severe familial hypertension. Biochem Biophys Res Commun 197:833–839[CrossRef][Medline]
101. Jeunemaitre X, Charru A, Chatellier G, Dumont C, Sassano P, Soubrier F, Ménard J, Corvol P 1993 M235T variant of the human angiotensinogen gene in unselected hypertensive patients. J Hypertens 11 [Suppl 5]:S80–S81
102. Schmidt S, Sharma AM, Zilch O, Beige J, Walla-Friedel M, Ganten D, Distler A, Ritz E 1995 Association of M235T variant of the angiotensinogen gene with familial hypertension of early onset. Nephrol Dial Transplant 10:1145–1148[Abstract/Free Full Text]
103. Hegele RA, Brunt H, Connelly PW 1994 A polymorphism of the angiotensinogen gene associated with variation in blood pressure in a genetic isolate. Circulation 90:2207–2212[Abstract/Free Full Text]
104. Hegele RA, Brunt JH, Connelly PW 1996 Genetic and biochemical factors associated with variation in blood pressure in a genetic isolate. Hypertension 27:308–312[Abstract/Free Full Text]
105. Barley J, Blackwood A, Sagnella G, Markandu N, MacGregor G, Carter N 1994 Angiotensinogen Met235Thr polymorphism in a London normotensive and hypertensive black and white population. J Hum Hypertens 8:639–640
106. Fornage M, Turner ST, Sing CF, Boerwinkle E 1995 Variation at the M235T locus of the angiotensinogen gene and essential hypertension: a population-based case-control study from Rochester, Minnesota. Hum Genet 96:295–300[Medline]
107. Hingorami AD, Sharma P, Jia H, Hopper R, Brown MJ 1996 Blood pressure and the M235T polymorphism of the angiotensinogen gene. Hypertension 28:907–911[Abstract/Free Full Text]
108. Kiema TR, Kauma H, Rantala AO, Lilja M, Reunanen A, Kesaniemi YA, Savolainen MJ 1996 Variation at the angiotensin-converting enzyme gene and angiotensinogen loci in relation to blood pressure. Hypertension 28:1070–1075[Abstract/Free Full Text]
109. Borecki IB, Province MA, Ludwig EH, Ellison RC, Folsom AR, Heiss G, Lalouel JM, Higgins M, Rao DC 1997 Associations of candidate loci angiotensinogen and angiotensin-converting enzyme with severe hypertension: the NHLBI Family Heart Study. Ann Epidemiol 7:13–21
110. Jeunemaitre X, Inoue I, Williams C, Charru A, Tichet J, Powers M, Sharma AM, Gimenez-Roqueplo A-P, Hata A, Corvol P, Lalouel J-M 1997 Haplotypes of angiotensinogen in essential hypertension. Am J Hum Genet 51:1448–1460
111. Schunkert H, Hense HW, Gimenez-Roqueplo A-P, Stieber J, Keil U, Riegger GAJ, Jeunemaitre X 1997 The angiotensinogen T235 variant and the use of antihypertensive drugs in a population based-cohort. Hypertension 29:628–633[Abstract/Free Full Text]
112. Nishiuma S, Kario K, Kayaba K, Nagio N, Shimada K, Matsuo T, Matsuo M 1995 Effect of the angiotensinogen gene Met235Thr variant on blood pressure and other cardiovascular risk factors in two Japanese populations. J Hypertens 13:717–722[Medline]
113. Hata A, Namikawa C, Sasaki M, Sato M, Nakamura T, Tamura K, Lalouel J-M 1994 Angiotensinogen as a risk factor for essential hypertension in Japan. J Clin Invest 93:1285–1287
114. Kamitani A, Raguki H, Higaki J, Yi Z, Mikami H, Miki T, Ogihara T 1994 Association analysis of a polymorphism of the angiotensinogen gene with essential hypertension in Japanese. J Hum Hypertens 8:521–524[Medline]
115. Iwai N, Ohmichi N, Nakamura Y, Mitsunami K, Kinoshito M 1994 Molecular variants of the angiotensinogen gene in a Japanese population. Hypertens Res 17:117–121[CrossRef]
116. Morise T, Takeuchi Y, Takeda R 1995 Rapid detection and prevalence of the variants of the angiotensinogen gene in patients with essential hypertension. J Intern Med 235:175–180
117. Iwai N, Shimoike H, Ohmichi N, Kinoshita M 1995 Angiotensinogen gene and blood pressure in the japanese population. Hypertension 25 [part 2]:688–693
118. Rutledge DR, Browes CS, Ross EA 1994 Frequencies of the angiotensinogen gene and angiotensin I converting enzyme (ACE) gene polymorphisms in African Americans. Biochem Mol Biol Int 34:1271–1275[Medline]
119. Forrester T, McFarlane-Anderson N, Bennet F, Wilks R, Puras A, Cooper R, Rotimin C, Durazo R, Tewksbury D, Morrison L 1996 Angiotensinogen and blood pressure among blacks: findings from a community survey in Jamaica. J Hypertens 14:315–321[CrossRef][Medline]
120. Nishimura H 1978 Physiological evolution of the renin-angiotensin system. Jpn Heart J 19:806–822[Medline]
121. Sutherland A, Cooper DW, Howie PW, Liston W, MacGillivray I 1981 The incidence of severe pre-eclampsia amongst mothers and mothers-in-law of pre-eclamptics and controls. Br J Obstet Gynaecol 88:785–791[Medline]
122. Chesley LC, Cooper DW 1986 Genetics of hypertension in pregnancy: possible single gene control of pre-eclampsia and eclampsia in the descendants of eclamptic women. Br J Obstet Gynaecol 93:898–903[Medline]
123. Ward K, Hata A, Jeunemaitre X, Helin C, Nelson L, Namikawa C, Farrington PF, Ogasawara M, Suzumori K, Tomoda S, Berrebi S, Sasaki M, Corvol P, Lifton RP, Lalouel J-M 1993 A molecular variant of angiotensinogen associated with preeclampsia. Nat Genet 4:59–61[CrossRef][Medline]
124. Arngrimsson R, Purandare S, Connor M, Walker JJ, Björnsson S, Soubrier F, Kotelevtsev YV, Geirsson RT, Björnsson H 1993 Angiotensinogen: a candidate gene involved in preeclampsia? Nat Genet 4:114–115[CrossRef][Medline]
125. Kobashi G 1995 A case-control study of pregnancy-induced hypertension with a genetic predisposition: association of a molecular variant of angiotensinogen in the Japanese woman. Hokkaido Igaku Zasshi 70:649–657[Medline]
126. Wilton AN, Kaye JA, Guo G, Brennecke P, Cooper DW 1995 Is angiotensinogen a good candidate gene for preeclampsia? Hypertens Pregnancy 14:251–260
127. Morgan L, Baker P, Pipkin FB, Kalsheker N 1995 Pre-eclampsia and the angiotensinogen gene. Br J Obstet Gynaecol 102:489–490[Medline]
128. Walker WG, Whelton PK, Saito H, Russel RP, Hermann J 1979 Relation between blood pressure and renin, renin substrate, angiotensin II, aldosterone and urinary sodium and potassium in 574 ambulatory subjects. Hypertension 1:287–291[Abstract/Free Full Text]
129. Fasola AF, Martz BL, Helmer OM 1968 Plasma renin activity during supine exercise in offspring of hypertensive patients. J Appl Physiol 25:410–415
130. Watt GC, Harrap SB, Foy CJ, Holton DW, Edwards HV, Davidson HR, Connor JM, Lever AF, Fraser R 1992 Abnormalities of glucocorticoid metabolism and the renin angiotensin system: a four-corners approach to the identification of genetic determinants of blood pressure. J Hypertens 10:473–482[Medline]
131. Ueno N, Yoshida K, Hirose S, Yokoyama H, Uehara H, Murakami K 1984 Angiotensinogen-producing hepatocellular carcinoma. Hypertension 6:931–933[Abstract/Free Full Text]
132. Kew MC, Leckie BJ, Greef MC 1989 Arterial hypertension as a paraneoplastic phenomenon in hepato cellular carcinoma. Arch Intern Med 149:2111–2113[Abstract/Free Full Text]
133. Bloem LJ, Foroud TM, Ambrosius WT, Hanna MP, Tewksbury DA, Pratt JH 1997 An association of the angiotensinogen gene to serum angiotensinogen in blacks and whites. Hypertension 29:1078–1082[Abstract/Free Full Text]
134. Busjahn A, Knoblauch H, Knoblauch M, Bohlender J, Menz M, Faulhaber H-D, Becker A, Schuster H, Luft FC 1997 Angiotensin-converting enzyme and angiotensinogen gene polymorphisms, plasma levels, cardiac dimensions. A twin study. Hypertension 29:165–170[Abstract/Free Full Text]
135. Williams GH, Hollenberg NK 1991 Non-modulating hypertension. A subset of sodium-sensitive hypertension. Hypertension 17 [Suppl I]:I81–I85
136. Williams GH, Dluhy RG, Lifton RP, Moore TJ, Gleason R, Williams RR, Hunt SC, Hopkins PN, Hollenberg NK 1992 Non-modulation as an intermediate phenotype in essential hypertension. Hypertension 20:788–796[Abstract/Free Full Text]
137. Hopkins PN, Lifton RP, Hollenberg NK, Jeunemaitre X, Hallouin M-C, Skuppin J, Williams CS, Dluhy RG, Lalouel J-M, Williams RR, Williams GH 1996 Blunted renal vascular response to angiotensin II is associated with a common variant of the angiotensinogen gene and obesity. J Hypertens 14:199–207[CrossRef][Medline]
138. Cambien F, Poirier O, Lecerf L, Evans A, Cambou J-P, Arveiler D, Luc G, Bard J-M, Bara L, Ricard S, Tiret L, Amouyel P, Alhenc-Gelas F, Soubrier F 1992 Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 359:641–644[CrossRef][Medline]
139. Tiret L, Ricard S, Poirier O, Arveiler D, Cambou J-P, Luc G, Evans A, Nicaud V, Cambien F 1995 Genetic variation at the angiotensinogen locus in relation to high blood pressure and myocardial infarction: the ECTIM study. J Hypertens 13:311–317[Medline]
140. Ishigami T, Umemura S, Iwamoto T, Tamura K, Hibi K, Yamaguchi S, Nyuui N, Kimura K, Miyazaki N, Ishii M 1995 Molecular variant of angiotensinogen gene is associated with coronary atherosclerosis. Circulation 91:951–954[Abstract/Free Full Text]
141. Katsuya T, Koike G, Yee TW, Sharpe N, Jackson R, Norton R, Horiuchi M, Pratt RE, Dzau VJ, MacMahon S 1995 Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease. Lancet 345:1600–1603[CrossRef][Medline]
142. Kamitani A, Rakugi H, Higaki J, Ohishi M, Shi SJ, Takami S, Nakata Y, Higashino Y, Fujii K, Mikami H, Miki T, Ogihara T 1995 Enhanced predictability of myocardial infarction in Japanese by combined genotype analysis. Hypertension 25:950–953[Abstract/Free Full Text]
143. Jeunemaitre X, Ledru F, Battaglia S, Guillanneuf M-T, Courbon D, Dumont C, Darmon O, Guize L, Guermonprez J-L, Diebold B, Ducimetière P 1997 Genetic polymorphisms of the renin-angiotensin system and angiographic extent and severity of coronary artery disease: the CORGENE study. Hum Genet 99:66–73[CrossRef][Medline]
144. Marre M 1996 Diabetic nephropathy: the ACE hypothesis. J Diabetic Complications 10:126–128
145. Yoshida H, Kon V, Ichikawa I 1996 Polymorphisms of the renin-angiotensin system genes in progressive renal diseases. Kidney Int 50:732–744[Medline]
146. Tarnow L, Cambien F, Rossing P, Nielsen FS, Hansen BV, Ricard S, Poirier O, Parving HH 1996 Angiotensinogen gene polymorphism in IDDM patients with diabetic nephropathy. Diabetes 45:367–369[Abstract]
147. Doria A, Onuma T, Gearin G, Freire MB, Warram JH, Krolewski AS 1996 Angiotensinogen polymorphism M235T, hypertension and nephropathy in insulin-dependent diabetes. Hypertension 27:1134–1139[Abstract/Free Full Text]
148. Schmidt S, Giessel R, Bergis KH, Strojek K, Grzeszczak W, Ganten D, Ritz E 1996 Angiotensinogen gene M235T polymorphism is not associated with diabetic nephropathy. The Diabetic Nephropathy Study Group. Nephrol Dial Transplant 11:1755–1761[Abstract/Free Full Text]
149. Fogarty DG, Harron JC, Hugues AE, Nevin NC, Doherty CC, Maxwell AP 1996 A molecular variant of angiotensinogen is associated with diabetic nephropathy in IDDM. Diabetes 45:1204–1208[Abstract]
150. Marre M, Jeunemaitre X, Gallois Y, Rodier M, Chatellier G, Sert C, Dusselier L, Kahal Z, Chaillou L, Halimi S, Muller A, Sackmann H, Bauduceau B, Bled F, Passa P, Alhenc-Gelas F 1997 Contribution of genetic polymorphisms of the renin angiotensin system to the development of renal complications in insulin-dependent diabetes. J Clin Invest 99:1585–1595
151. Eggena P, Sowers J, Maxwell MH, Barrett JD, Golub MS 1991 Hormonal correlates of weight loss associated with blood pressure reduction. Clin Exp Hypertens [A] 13:1447–1456[Medline]
152. Kanai H, Matsuzawa Y, Kotani K, Keno Y, Kobatake T, Nagai Y, Fujioka S, Tokunaga K, Tarui S 1990 Close correlation of intra-abdominal fat accumulation to hypertension in obese women. Hypertension 16:484–490[Abstract/Free Full Text]
153. Inoue I, Rohrwasser A, Helin C, Jeunemaitre X, Crain P, Bohlender J, Lifton RP, Corvol P, Ward K, Lalouel J-M 1995 A mutation of angiotensinogen in a patient with preeclampsia leads to altered kinetics of the renin angiotensin system. J Biol Chem 270:11430–11436[Abstract/Free Full Text]
154. Gimenez-Roqueplo A-P, Leconte I, Cohen P, Simon D, Guyene T-T, Celerier J, Pau B, Corvol P, Clauser E, Jeunemaitre X 1996 The natural mutation Y248C of human angiotensinogen leads to abnormal glycosylation and altered immunological recognition of the protein. J Biol Chem 271:9838–9844[Abstract/Free Full Text]
155. Cohen P, Badouaille G, Gimenez-Roqueplo A-P, Mani JC, Guyene T-T, Jeunemaitre X, Ménard J, Corvol P, Pau B, Simon D 1996 Selective recognition of M235T angiotensinogen variants and their determination in human plasma by monoclonal antibody-based immunoanalysis. J Clin Endocrinol Metab 81:3505–3512[Abstract]
156. Lodwick D, Kaiser MA, Harris J, Cumin F, Vincent M, Samani NJ 1995 Analysis of the role of angiotensinogen in spontaneous hypertension. Hypertension 25:1245–1251[Abstract/Free Full Text]
157. Hübner N, Kreutz R, Takahashi S, Ganten D, Lindpaintner K 1994 Unlike human hypertension, blood pressure in a hereditary hypertensive rat strain shows no linkage to the angiotensinogen locus. Hypertension 23:797–801[Abstract/Free Full Text]
158. Hübner N, Kreutz R, Takahashi S, Ganten D, Lindpaintner K 1995 Altered angiotensinogen amino acid sequence and plasma angiotensin II levels in genetically hypertensive rats. A study on cause and effect. Hypertension 26:279–284[Abstract/Free Full Text]
159. Rapp JP, Wang SM, Dene H 1989 A genetic polymorphism in the renin gene of Dahl rats cosegregates with blood pressure. Science 243:542–544[Abstract/Free Full Text]
160. Iwai N, Inagami T 1992 Identification of a candidate gene responsible for the high blood pressure of spontaneously hypertensive rats. J Hypertens 10:1155–1157[CrossRef][Medline]
161. Nabika T, Bonnardeaux A, James M, Julier C, Jeunemaitre X, Corvol P, Lathrop M, Soubrier F 1995 Evaluation of the SA locus in human hypertension. Hypertension 25:6–13[Abstract/Free Full Text]
162. Pedrazzini T, Cousin P, Aubert JF, Brunner HR 1995 Transient inhibition of angiotensinogen production in transgenic mice bearing an antisense angiotensinogen gene. Kidney Int 47:1638–1646[Medline]
163. Tomita N, Morishita R, Higaki J, Aoki M, Nakamura Y, Mikami H, Fukamizu A, Murakami K, Kaneda Y, Ogihara T 1995 Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat angiotensinogen. Hypertension 26:131–136[Abstract/Free Full Text]
164. Wielbo D, Simon A, Philipps MI, Toffolo S 1996 Inhibition of hypertension by peripheral administration of antisense oligodeoxynucleotides. Hypertension 28:147–151[Abstract/Free Full Text]
165. Kimura S, Mullins JJ, Bunnemann B, Metzger R, Hilgenfeldt U, Zimmermann F, Jacob H, Fuxe K, Ganten D, Kaling M 1992 High blood pressure in transgenic mice carrying the rat angiotensinogen gene. EMBO J 11:821–827[Medline]
166. Ohkubo H, Kawakami H, Kakehi Y, Takumi T, Arai H, Yokota Y, Iwai M, Tanabe Y, Masu M, Hata J, Iwao H, Okamoto H, Yokoyoama M, Nomura T, Katsuki M, Nakanishi S 1990 Generation of transgenic mice with elevated blood pressure by introduction of the rat renin and angiotensinogen genes. Proc Natl Acad Sci USA 87:5153–5157[Abstract/Free Full Text]
167. Fukamizu A, Sugimura K, Takimoto E, Sugiyama F, Seo MS, Takahashi S, Hatae T, Kajiwara N, Yagami K, Murakami K 1993 Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. J Biol Chem 268:11617–11621[Abstract/Free Full Text]
168. Bouhnik J, Clauser E, Strosberg D, Frenoy J-P, Ménard J, Corvol P 1981 Rat angiotensinogen and des(angiotensin I)angiotensinogen: purification, characterization, and partial sequencing. Biochemistry 20:7010–7015[CrossRef][Medline]
169. Takimoto E, Ishida J, Sugiyama F, Horiguchi H, Murakami K, Fukamizu A 1996 Hypertension induced in pregnant mice by placental renin and maternal angiotensinogen. Science 274:995–998[Abstract/Free Full Text]
170. Smithies O, Kim HS 1994 Targeted gene duplication and disruption for analyzing quantitative genetic traits in mice. Proc Natl Acad Sci USA 91:3612–3615[Abstract/Free Full Text]
171. Kim HS, Krege JH, Kluckman KD, Hagaman JR, Hodgin JB, Best CF, Jennette C, Coffman TM, Maeda N, Smithies O 1995 Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci USA 92:2735–2739[Abstract/Free Full Text]
172. Dudley C, Keavney B, Casadei B, Conway J, Bird R, Ratcliffe P 1996 Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: Investigation of the renin-angiotensin system genes. J Hypertens 14:259–262[CrossRef][Medline]

This article has been cited by other articles:

				F. Vincent, P. Bonnin, M. Clemessy, J.-O. Contreres, N. Lamande, J.-M. Gasc, J. Vilar, P. Hainaud, G. Tobelem, P. Corvol, et al. Angiotensinogen Delays Angiogenesis and Tumor Growth of Hepatocarcinoma in Transgenic Mice Cancer Res., April 1, 2009; 69(7): 2853 - 2860. [Abstract] [Full Text] [PDF]

				S. Sriramula, M. Haque, D. S.A. Majid, and J. Francis Involvement of Tumor Necrosis Factor-{alpha} in Angiotensin II-Mediated Effects on Salt Appetite, Hypertension, and Cardiac Hypertrophy Hypertension, May 1, 2008; 51(5): 1345 - 1351. [Abstract] [Full Text] [PDF]

				T. V. Pereira, A. C.F. Nunes, M. Rudnicki, Y. Yamada, A. C. Pereira, and J. E. Krieger Meta-Analysis of the Association of 4 Angiotensinogen Polymorphisms With Essential Hypertension: A Role Beyond M235T? Hypertension, March 1, 2008; 51(3): 778 - 783. [Abstract] [Full Text] [PDF]

				S. Jain, Y. Li, S. Patil, and A. Kumar HNF-1{alpha} plays an important role in IL-6-induced expression of the human angiotensinogen gene Am J Physiol Cell Physiol, July 1, 2007; 293(1): C401 - C410. [Abstract] [Full Text] [PDF]

				H. Schmidt, Y. S. Aulchenko, N. Schweighofer, R. Schmidt, S. Frank, G. M. Kostner, E. Ott, and C. van Duijn Angiotensinogen Promoter B-Haplotype Associated With Cerebral Small Vessel Disease Enhances Basal Transcriptional Activity Stroke, November 1, 2004; 35(11): 2592 - 2597. [Abstract] [Full Text] [PDF]

				T. A. Manolio, E. Boerwinkle, C. J. O'Donnell, and A. F. Wilson Genetics of Ultrasonographic Carotid Atherosclerosis Arterioscler. Thromb. Vasc. Biol., September 1, 2004; 24(9): 1567 - 1577. [Abstract] [Full Text] [PDF]

				Y. Guo, E. Mascareno, and M. A. Q. Siddiqui Distinct Components of Janus Kinase/Signal Transducer and Activator of Transcription Signaling Pathway Mediate the Regulation of Systemic and Tissue Localized Renin-Angiotensin System Mol. Endocrinol., April 1, 2004; 18(4): 1033 - 1041. [Abstract] [Full Text] [PDF]

				Y. Shimamoto, J. Ishida, K. Yamagata, T. Saito, H. Kato, T. Matsuoka, K. Hirota, H. Daitoku, M. Nangaku, K. Yamagata, et al. Inhibitory Effect of the Small Heterodimer Partner on Hepatocyte Nuclear Factor-4 Mediates Bile Acid-induced Repression of the Human Angiotensinogen Gene J. Biol. Chem., February 27, 2004; 279(9): 7770 - 7776. [Abstract] [Full Text] [PDF]

				S. Jain, X. Tang, C. S. Narayanan, Y. Agarwal, S. M. Peterson, C. D. Brown, J. Ott, and A. Kumar Angiotensinogen Gene Polymorphism at -217 Affects Basal Promoter Activity and Is Associated with Hypertension in African-Americans J. Biol. Chem., September 20, 2002; 277(39): 36889 - 36896. [Abstract] [Full Text] [PDF]

				A. R. Brasier, A. Recinos III, and M. S. Eledrisi Vascular Inflammation and the Renin-Angiotensin System Arterioscler. Thromb. Vasc. Biol., August 1, 2002; 22(8): 1257 - 1266. [Abstract] [Full Text] [PDF]

				J. Celerier, A. Cruz, N. Lamande, J.-M. Gasc, and P. Corvol Angiotensinogen and Its Cleaved Derivatives Inhibit Angiogenesis Hypertension, February 1, 2002; 39(2): 224 - 228. [Abstract] [Full Text] [PDF]

				R. S. Danziger Hypertension in an Anthropological and Evolutionary Paradigm Hypertension, July 1, 2001; 38(1): 19 - 22. [Full Text] [PDF]

				C. T. Sherman and A. R. Brasier Role of Signal Transducers and Activators of Transcription 1 and -3 in Inducible Regulation of the Human Angiotensinogen Gene by Interleukin-6 Mol. Endocrinol., March 1, 2001; 15(3): 441 - 457. [Abstract] [Full Text]

				M. Azizi, M.-C. Hallouin, X. Jeunemaitre, T. T. Guyene, and J. Ménard Influence of the M235T Polymorphism of Human Angiotensinogen (AGT) on Plasma AGT and Renin Concentrations after Ethinylestradiol Administration J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4331 - 4337. [Abstract] [Full Text]

				S. B. Harrap, A. D. Cumming, D. L. Davies, C. J. W. Foy, R. Fraser, A. Kamitani, J. M. Connor, A. F. Lever, and G. C. M. Watt Glomerular Hyperfiltration, High Renin, and Low- Extracellular Volume in High Blood Pressure Hypertension, April 1, 2000; 35(4): 952 - 957. [Abstract] [Full Text] [PDF]

				J. Celerier, G. Schmid, J.-P. Le Caer, A.-P. Gimenez-Roqueplo, D. Bur, A. Friedlein, H. Langen, P. Corvol, and X. Jeunemaitre Characterization of a Human Angiotensinogen Cleaved in Its Reactive Center Loop by a Proteolytic Activity from Chinese Hamster Ovary Cells J. Biol. Chem., March 31, 2000; 275(14): 10648 - 10654. [Abstract] [Full Text] [PDF]

				J. Bohlender, J. Menard, D. Ganten, and F. C. Luft Angiotensinogen Concentrations and Renin Clearance : Implications for Blood Pressure Regulation Hypertension, March 1, 2000; 35(3): 780 - 786. [Abstract] [Full Text] [PDF]

				O. A. Carretero and S. Oparil Essential Hypertension : Part I: Definition and Etiology Circulation, January 25, 2000; 101(3): 329 - 335. [Full Text] [PDF]

				C. Fardella, P. Zamorano, L. Mosso, L. Gomez, M. Pinto, J. Soto, E. Oestreicher, P. Cortes, X. Claverie, and J. Montero A-6G Variant of Angiotensinogen Gene and Aldosterone Levels in Hypertensives Hypertension, October 1, 1999; 34(4): 779 - 781. [Abstract] [Full Text] [PDF]

				J. Karjalainen, U. M. Kujala, A. Stolt, M. Mantysaari, M. Viitasalo, K. Kainulainen, and K. Kontula Angiotensinogen gene M235T polymorphism predicts left ventricular hypertrophy in endurance athletes J. Am. Coll. Cardiol., August 1, 1999; 34(2): 494 - 499. [Abstract] [Full Text] [PDF]

				J. Baima, M. Nicolaou, F. Schwartz, A. L. DeStefano, A. Manolis, I. Gavras, C. Laffer, F. Elijovich, L. Farrer, C. T. Baldwin, et al. Evidence for Linkage Between Essential Hypertension and a Putative Locus on Human Chromosome 17 Hypertension, July 1, 1999; 34(1): 4 - 7. [Abstract] [Full Text] [PDF]

				P. Corvol, A. Persu, A.-P. Gimenez-Roqueplo, and X. Jeunemaitre Seven Lessons From Two Candidate Genes in Human Essential Hypertension : Angiotensinogen and Epithelial Sodium Channel Hypertension, June 1, 1999; 33(6): 1324 - 1331. [Abstract] [Full Text] [PDF]

				H. M. Siragy, T. Inagami, T. Ichiki, and R. M. Carey Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor PNAS, May 25, 1999; 96(11): 6506 - 6510. [Abstract] [Full Text] [PDF]

				A.-P. Gimenez-Roqueplo, J. Celerier, G. Schmid, P. Corvol, and X. Jeunemaitre Role of Cysteine Residues in Human Angiotensinogen. CYS232 IS REQUIRED FOR ANGIOTENSINOGEN-PRO MAJOR BASIC PROTEIN COMPLEX FORMATION J. Biol. Chem., December 18, 1998; 273(51): 34480 - 34487. [Abstract] [Full Text] [PDF]

				A.-P. Gimenez-Roqueplo, J. Celerier, G. Lucarelli, P. Corvol, and X. Jeunemaitre Role of N-Glycosylation in Human Angiotensinogen J. Biol. Chem., August 14, 1998; 273(33): 21232 - 21238. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Corvol, P. Articles by Jeunemaitre, X. Search for Related Content PubMed PubMed Citation Articles by Corvol, P. Articles by Jeunemaitre, X.